Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2021 Dec 20;11:24254. doi: 10.1038/s41598-021-03260-5

MYCL promotes iPSC-like colony formation via MYC Box 0 and 2 domains

Chiaki Akifuji 1, Mio Iwasaki 1, Yuka Kawahara 1, Chiho Sakurai 1, Yu-Shen Cheng 1, Takahiko Imai 1, Masato Nakagawa 1,
PMCID: PMC8688507  PMID: 34930932

Abstract

Human induced pluripotent stem cells (hiPSCs) can differentiate into cells of the three germ layers and are promising cell sources for regenerative medicine therapies. However, current protocols generate hiPSCs with low efficiency, and the generated iPSCs have variable differentiation capacity among different clones. Our previous study reported that MYC proteins (c-MYC and MYCL) are essential for reprogramming and germline transmission but that MYCL can generate hiPSC colonies more efficiently than c-MYC. The molecular underpinnings for the different reprogramming efficiencies between c-MYC and MYCL, however, are unknown. In this study, we found that MYC Box 0 (MB0) and MB2, two functional domains conserved in the MYC protein family, contribute to the phenotypic differences and promote hiPSC generation in MYCL-induced reprogramming. Proteome analyses suggested that in MYCL-induced reprogramming, cell adhesion-related cytoskeletal proteins are regulated by the MB0 domain, while the MB2 domain regulates RNA processes. These findings provide a molecular explanation for why MYCL has higher reprogramming efficiency than c-MYC.

Subject terms: Stem cells, Reprogramming

Introduction

Human induced pluripotent stem cells (hiPSCs) are generated from somatic cells and can differentiate into cells of all three germ layers1,2. They are functionally identical to human embryonic stem cells (hESCs) but do not require the destruction of the embryo, which has made them attractive sources for regenerative medicine3. The original reprogramming was induced by four factors, OCT3/4, SOX2, KLF4, and c-MYC (OSKM). Since then, several new methods have been developed to improve the yield and quality of iPSCs, but the cost remains high and the production remains technically difficult4,5. Further complicating the application of hiPSCs is the wide variability in the differentiation capacity of different hiPSC clones6.

We have shown that excluding c-MYC from the reprogramming factors significantly lowers the reprogramming and differentiation efficiencies of the resulting iPSCs7. The MYC family consists of the oncogenes c-MYC, MYCN, and MYCL in humans8. c-MYC was the first MYC gene discovered in human and has been a topic of cancer research ever since9. Tumorigenesis depends on high transformation activity derived from the N-terminus region of c-MYC protein10. Consequently, OSKM-based reprogramming may not be appropriate for the clinical application of iPSCs. Many groups have reported reprogramming methods that exclude c-MYC overexpression but at the cost of lower reprogramming efficiency5,7. MYCL is about 30 amino acids shorter in the N-terminus region than c-MYC and has lower transformation activity10. We found that substituting c-MYC for MYCL in reprogramming can increase the number of iPSC colonies and maintain the ability to differentiate into the cells of three germ layers7. Furthermore, fewer chimeric mice died by tumorigenesis after the transplantation of MYCL-iPSCs, whereas the transplantation of c-MYC-iPSCs caused lethal tumorigenesis in more than 50% of mice during two years of observation. Despite these observations, little is known about the molecular function of MYCL and the different mechanisms between c-MYC and MYCL to promote reprogramming.

MYC proteins have six MYC Box (MB) domains: MB0, 1, 2, 3a, 3b, and 4 in the N-terminus and a basic helix-loop-helix leucine zipper (bHLHLZ) in the C-terminus11, but MYCL does not have MB3a. The C-terminus of c-MYC and MYCL is essential in reprogramming due to its binding with MAX protein, allowing MYC to access the DNA7,12. The N-terminus is mainly known as a transactivation domain (TAD), which regulates the target gene, but its function in reprogramming is less clear13. We found that a mutant of c-MYC lacking the N-terminal showed low transformation activity and promoted reprogramming7. However, which domain on the N-terminal side is essential for reprogramming and what function it performs were not resolved. In addition, MYC proteins act as transcription factors upon interacting with several binding proteins14. Although MYCL-binding proteins are important for MYCL function, there are no reports about MYCL-binding proteins during reprogramming.

In this study, using domain deletion mutants of MYC proteins, we found that the MB0 and MB2 domains promote iPSC-like colonies and that the MB0 domain is functionally different between c-MYC and MYCL. In c-MYC, it induced non-iPSC-like colonies by increasing nucleic proteins related to transcription, but in MYCL, the MB0 domain induced iPSC-like colonies by increasing the expression of cell adhesion-related proteins. We also found that deletion of the MB2 domain in MYC proteins prevented colony formation and that MYCL could interact with RNA-binding proteins (RBPs) via this domain. These results suggested that MYCL promotes reprogramming by regulating RNA processing.

Results

MYCL promotes reprogramming more efficiently than c-MYC

To compare the reprogramming phenotypes of MYCL and c-MYC, we used Sendai virus (SeV)-based reprogramming (CytoTune-iPS) and StemFit AK03N medium without bFGF (Fig. 1A). The SeV method has high reprogramming efficiency without genome integration, and c-MYC and MYCL SeV kits are already available15. The bFGF exclusion is based on the data in Supplementary Fig. S1. DMEM supplemented with 10% FBS (DMEM + 10%FBS) is the standard medium to induce reprogramming. We used DMEM + 10%FBS when introducing the reprogramming factors, but after 7 days of reprogramming, we replated the cells and used StemFit AK03N without bFGF (03N (-)) from that point on. The MOI (multiplicity of infection) of each SeV was 20. To improve the reprogramming efficiency, we compared three media combinations (Supplementary Fig. S1A). The highest number of colonies was obtained using 03N (-) during reprogramming and 03N ( +) after replating (Supplementary Fig. S1B). These results indicated that the 03N (-) reprogramming condition in the first 7 days enhances the reprogramming efficiency compared to 03N ( +). We then examined the optimal MOI of SeV for the reprogramming (Supplementary Fig. S1C). A lower MOI induced more colonies (Supplementary Fig. S1D), indicating a higher reprogramming efficiency. Following these results, we applied SeV for the transduction at an MOI of 4.3 using 03N (-) during reprogramming.

Figure 1.

Figure 1

MYCL promotes reprogramming more efficiently than c-MYC. (A) Schematic representation of HDF reprogramming with Sendai virus (SeV). HDFs were transduced with SeV carrying KLF4-OCT3/4-SOX2 (KOS), KLF4 (K), and c-MYC or MYCL on day 0. We used an MOI (multiplicity of infection) of 4.3 for each virus. StemFit AK03N without bFGF was used during the transduction and subsequent induction of iPSC-like colonies. We performed immunostaining of the reprogramming HDFs 1 to 7 days after the transduction and analyzed the results using ArrayScan. (B) Representative immunostaining images of reprogramming HDFs stained by anti-TRA-1-60 antibody (green) and Hoechst (blue) 7 days after the transduction. Scale bar, 300 μm. Ph, phase contrast. (C) Proliferation and expression of TRA-1-60 ( +) cells during reprogramming. HDFs were transduced with SeV, including c-MYC or MYCL, and immunostaining was performed from days 1 to 7. The number of total cells was counted as Hoechst-positive cells. Mean ± SD values are shown. n = 3, *p < 0.05 by paired t-test. (D) Schematic representation of HDF reprogramming with episomal plasmid vector (EpiP). HDFs were transduced with EpiP carrying SOX2, KLF4, OCT3/4-shp53, LIN28A, EBNA1, and c-MYC or MYCL. StemFit AK03N without bFGF was used during the transfection and subsequent induction of iPSC-like colonies. We performed flow cytometry of the reprogramming HDFs every three days from 1 to 19 days plus day 21 after the transduction. (E) Representative immunostaining images of reprogramming HDFs stained by anti-TRA-1-60 antibody (green) and Hoechst (blue) 21 days after the transduction. Scale bar, 300 μm. Ph, phase contrast. (F) Proliferation and expression of TRA-1-60 ( +) cells during reprogramming were analyzed by flow cytometry. HDFs were transduced with EpiP, including c-MYC or MYCL. Flow cytometry was performed every three days from days 1 to 19 days plus day 21. Mean ± SD for n = 3, *p < 0.05 and **p < 0.01 by paired t-test. (G) The number of iPSC-like and non-iPSC-like colonies derived from 1 × 105 HDFs transduced with EpiP including c-MYC or MYCL on day 21. Mean ± SD values are shown. n = 3, **p < 0.01 by unpaired t-test. (H) Percentage of CD13 ( +) cells during EpiP reprogramming determined by flow cytometry. Mean ± SD values are shown. n = 3, *p < 0.05 and **p < 0.01 by paired t-test.

Next, we conducted immunostaining to analyze the expression of TRA-1-60 from days 1 to 7 after the transduction (Fig. 1A). TRA-1-60 is a glycoprotein and major cell surface marker of hiPSCs and hESCs16. We quantified the results using a high-content imaging system, ArrayScan, because the cell number was small during SeV reprogramming for the first seven days, making flow cytometry challenging. On day 7, we observed that c-MYC and MYCL induced a small cell mass to form colonies, but only the colonies induced by MYCL expressed TRA-1-60, while those induced by c-MYC looked like cell aggregations (Fig. 1B and Supplementary Fig. S2). Cell proliferation was highly increased in human dermal fibroblasts (HDFs) transduced with c-MYC compared to MYCL. On the other hand, the percentage of TRA-1-60 ( +) cells increased more in MYCL-transduced HDFs on day 3 after the transduction (Fig. 1C). This difference may be because c-MYC has higher transformation activity than MYCL, which causes different phenotypes, especially cell proliferation10.

We confirmed these reprogramming phenotypes using episomal plasmid vector (EpiP)17 (Fig. 1D). SeV systems have a higher gene transfer efficiency, leading to more efficient reprogramming. However, we could modify the reprogramming vectors, which is useful for evaluating the molecular mechanism of c-MYC and MYCL, only when using the EpiP system.

Similar to the results with the SeV method, few colonies expressed TRA-1-60 in c-MYC-transfected HDFs (Fig. 1E and Supplementary Fig. S3A). However, the transfection of MYCL resulted in a higher percentage of TRA-1-60 ( +) cells and lower cell proliferation than the transfection of c-MYC (Fig. 1F and Supplementary Fig. S3B). These differences between MYCL and c-MYC were more obvious with EpiP reprogramming than SeV reprogramming (Fig. 1C, F), probably because of differences in the gene transfer efficiency15,17, the expression of the transfected factors, cell toxicity, and the time required for the iPSC-like colonies to appear: the SeV system requires about 7 days, but the EpiP system needs about 21 days based on our observations.

We found two types of colonies: “iPSC-like” and “non-iPSC-like” colonies. The iPSC-like colonies produced by MYCL were more flattened and showed a monolayered colony morphology, with each cell tightly packed and expressing TRA-1-60. The non-iPSC-like colonies produced by c-MYC showed a cell aggregation-like morphology, in which individual cells were irregularly aggregated and did not express TRA-1-60. We counted the number of iPSC-like and non-iPSC-like colonies on day 21 and found that c-MYC induced iPSC-like colonies as well as many non-iPSC-like colonies, but MYCL induced almost only iPSC-like colonies and more of them than c-MYC (Fig. 1G and Supplementary Fig. S3).

It has been reported that before the increase in the expression of TRA-1-60, a decrease in the expression of CD13, a marker of fibroblasts18, is observed in somatic cell reprogramming. Therefore, we confirmed the expression of CD13 during reprogramming. The percentage of CD13 ( +) cells decreased daily in HDFs transduced with c-MYC or MYCL, but the number of CD13 (-) cells rapidly increased in c-MYC compared to MYCL (Fig. 1H and Supplementary Fig. S4). In particular, the CD13 (-) TRA-1-60 (-) population was larger on day 10 with c-MYC reprogramming than MYCL reprogramming, but the CD13 (-) TRA-1-60 ( +) population from days 16 to 21 was larger with MYCL reprogramming (Supplementary Fig. S4). These results suggested that MYCL promotes TRA-1-60 ( +) cells more than c-MYC, but c-MYC suppresses CD13 expression more than MYCL.

MYC Box 0 and 2 domains are crucial for colony formation during reprogramming

Next, we prepared domain deletion mutants to identify which domains in the N-terminus of MYC proteins influence reprogramming (Fig. 2A and Supplementary Fig. S5). We previously showed that a c-MYC mutant lacking transformation activity enhances the formation of iPSC-like colonies. This mutant has a point mutation in the transactivation domain of the N-terminal region, W135E (Fig. 2A and Supplementary Fig. S5B), but can bind to genomic DNA7. On the other hand, the bHLHLZ domain in the C-terminus region is a well-known binding domain of MAX19. Mutants in the C-terminus region prevent MYC proteins from binding to DNA and thus reprogramming7. Finally, we tested the reprogramming activities of these mutants using the EpiP reprogramming system because, as explained above, this method provided a clearer phenotype and was easier to manipulate than the SeV method.

Figure 2.

Figure 2

MYC Box 0 and 2 domains are crucial for colony formation during reprogramming. (A) Schematic representation of WT c-MYC and MYCL protein. Black boxes show important domains for MYC function, including MB0, 1, 2, 3a (c-MYC only), 3b, 4, and basic-helix-loop-helix leucine zipper motif (bHLHLZ). The percentage of common amino acids in each MYC box domain between MYCL and c-MYC is shown (Identity%). The numbers on the right indicate amino acid lengths. (B) Number of iPSC-like and non-iPSC-like colonies transduced with EpiP including c-MYC-WT/mutants (left) or MYCL-WT/mutants (right) on day 21. Mean ± SD values are shown. n = 3, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by ordinary one-way ANOVA and Dunnett’s test vs. WT. (C) Expression of TRA-1-60 ( +) HDFs and CD13 ( +) HDFs transduced with EpiP including c-MYC-WT/mutants (left) or MYCL-WT/mutants (right) on day 16. Mean ± SD values are shown. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by ordinary one-way ANOVA and Dunnett’s test vs. WT. (D) Representative flow cytometry images for TRA-1-60 and CD13 for HDFs transduced with EpiP including c-MYC-WT/ΔMB0 or MYCL-WT/ΔMB0 10 and 21 days after the transduction. Numbers indicate the expression percentage of each quadrant. (E) Proliferation of HDFs transduced with EpiP including c-MYC-WT/ΔMB0 or MYCL-WT/ΔMB0 10 and 21 days later. Mean ± SD values are shown. n = 3, ***p < 0.001 by ordinary one-way ANOVA and Dunnett’s test vs. c-MYC-WT. The number of cells was counted using a Cell Counter model R1 (OLYMPUS).

The EpiP mutants were transfected into HDFs with other reprogramming factors, and the number of iPSC-like and non-iPSC-like colonies was counted (Fig. 2B and Supplementary Fig. S6). c-MYC-ΔMB0 promoted the formation of iPSC-like colonies and inhibited the formation of non-iPSC-like colonies compared to c-MYC-WT. In contrast, MYCL-ΔMB0 showed almost no ability to form iPSC-like colonies (Fig. 2B). We confirmed that the protein expression of each domain deletion mutant by western blotting showed no difference compared with c-MYC- or MYCL-WT (Supplementary Fig. S7 and S8). These results demonstrate that the MB0 domain has different functions in c-MYC and MYCL for reprogramming and that c-MYC-ΔMB0 has a similar function as MYCL-WT.

Figure 2B shows that c-MYC-ΔMB1 promoted iPSC-like colony formation like c-MYC-ΔMB0, but it also led to the formation of non-iPSC-like colonies. The formation of iPSC-like colonies by MYCL-ΔMB1 was about a quarter that by MYCL-WT. Unlike c-MYC-WT, c-MYC-ΔMB2 did not induce non-iPSC-like colonies, but it did induce a rate of iPSC-like colonies similar to c-MYC-WT. MYCL-ΔMB2 showed little ability to form iPSC-like colonies, resembling MYCL-ΔMB0. c-MYC-ΔMB3a, -ΔMB3b, and -ΔMB4 had similar colony-forming activities as c-MYC-WT. MYCL-ΔMB3b showed the same reprogramming efficiency as MYCL-WT, but MYCL-ΔMB4 formed about the same small number of iPSC-like colonies as MYCL-ΔMB1. The ΔbHLHLZ mutants of both c-MYC and MYCL failed to induce colonies and were therefore considered to have lost MYC function completely. Thus, the results indicate that in c-MYC, the MB0 and MB2 domains are repressive for iPSC-like colony formation, but in MYCL, they are promotive. Other domains also influenced the colony formation efficiency, but the effect was small.

Next, we analyzed the effect of the MYC-deletion mutants on the expression of TRA-1-60 and CD13 by flow cytometry 16 days after the start of reprogramming (Fig. 2C). Mutants that increased the number of iPSC-like colonies also increased the expression of TRA-1-60, while those that reduced the number of iPSC-like colonies lowered the TRA-1-60 expression (Fig. 2C and Supplementary Fig. S9). c-MYC-WT showed little TRA-1-60 expression, whereas c-MYC-ΔMB0 upregulated the expression. MYCL-ΔMB0, unlike MYCL-WT, failed to upregulate the expression of TRA-1-60. The CD13 expression was also correlated with colony formation. In c-MYC, a significant decrease in CD13 expression was observed for mutants that promoted non-iPSC-like colony formation. As for MYCL, only a slight decrease in CD13 expression was observed for mutants that promoted iPSC-like colony formation. From these results, we concluded that the MB0 domain is essential for the function of MYC in reprogramming but functions differently between c-MYC and MYCL.

To analyze the function of the MB0 domain in more detail, we analyzed the expression of TRA-1-60 and CD13 10 and 21 days after the start of reprogramming by flow cytometry (Fig. 2D). In the case of c-MYC-WT, there was a strong decrease in CD13 expression on day 10, and most cells were CD13 negative on day 21. In the cases of c-MYC-ΔMB0 and MYCL-WT, there was a slight decrease in CD13 expression on day 10, and more than half of cells were expressing TRA-1-60 on day 21. Finally, in the case of MYCL-ΔMB0, there was no change in CD13 or TRA-1-60 expression. More study is needed to determine how CD13 is regulated by c-MYC and MYCL.

Additionally, c-MYC-WT showed higher cell proliferation on day 10, but c-MYC-ΔMB0 resulted in a lower cell proliferation comparable more with MYCL-WT than with c-MYC-WT on day 10 (Fig. 2E). We attributed this effect to the lost transformation activity of c-MYC-ΔMB0. From days 10 to 21, the cell proliferation increased significantly in c-MYC-ΔMB0 and MYCL-WT, and a concomitant increase in the CD13 (-) TRA-1-60 ( +) population was observed (Fig. 2D, E). These observations suggest that the number of cells that were reprogrammed increased rapidly with c-MYC-ΔMB0 and MYCL-WT. With c-MYC-WT, the cell proliferation continued until day 21. However, the CD13 (-) TRA-1-60 ( +) population hardly increased (Fig. 2D), indicating that these cells were not reprogramming but changing to other highly proliferative cell types. From these results, we concluded that the MB0 domain functions negatively in c-MYC and positively in MYCL for reprogramming.

MYCL regulates cytoskeleton- and cell adhesion-related proteins during reprogramming via the MB0 domain

To confirm which genes are regulated by the MYCL MB0 domain in reprogramming, we analyzed protein expressions during reprogramming because it was reported that gene expressions do not correlate well with protein expressions20. We performed a comprehensive analysis of expressed proteins during reprogramming induced by c-MYC and MYCL WT and ΔMB0 mutants. We used SeV-reprogramming HDFs on days 3, 5, and 7 days and EpiP-reprogramming HDFs on day 10 as samples for mass spectrometry (MS) (Fig. 3A) because the percentage of TRA-1-60 ( +) cells was much higher with SeV than with EpiP for observations up to day 7 (Fig. 1C, F). There was more than a two-fold increase in the expression of 520 (SeV) and 128 (EpiP) proteins with MYCL-WT reprogramming compared to c-MYC-WT reprogramming (Fig. 3B, groups (i) and (ii), respectively) and 183 (EpiP) proteins with c-MYC-ΔMB0 reprogramming compared to c-MYC-WT reprogramming (Fig. 3B, group (iii)). Overall, we identified 18 proteins common to the three groups (Fig. 3B, group (iv)). Then, we applied a Gene Ontology (GO) analysis using DAVID and detected enriched terms during reprogramming21,22 (Fig. 3C, D, and Table 1), finding cytoskeleton- and cell adhesion-related proteins are involved in the promotion of reprogramming by MYCL-WT. The same analysis was performed to identify proteins whose expression was upregulated by c-MYC-WT compared with MYCL-WT and c-MYC-ΔMB0 (Supplementary Fig. S10A and Table 2). These proteins were associated with the proliferation of non-iPSC-like colonies. We found that c-MYC-WT regulates proteins involved in cell proliferation, such as the cell cycle and DNA replication. To understand the function of the MB0 domain in reprogramming, MS analysis was applied to HDF samples transfected with MYCL-WT, MYCL-ΔMB0, or c-MYC-ΔMB0 (Supplementary Fig. S10B and Table 3). GO analysis indicated that these proteins were associated with cell adhesion and RNA processing.

Figure 3.

Figure 3

MYCL regulates cytoskeleton- and cell adhesion-related proteins during reprogramming via the MB0 domain. (A) Schematic of the mass spectrometry (MS) and GO analysis (DAVID). (B) Venn diagram of upregulated proteins during iPSC-like colony formation. (C) Molecular functions from the GO analysis of the four groups in (B). (D) KEGG pathways from the GO analysis of the four groups in (B).

Table 1.

MS analysis of identified proteins in cells reprogrammed by MYCL- or c-MYC-ΔMB0.

(i) Proteins enriched more than two-fold in MYCL-WT compared with c-MYC-WT (SeV)
NRP1 PMEL IQCH ZNF507 C1QTNF3 GLIPR2
ING1 THOC7 RPAIN DGCR8 KRAS PIPOX
CCNL2 ACOT8 KCNMA1 TTC38 MRI1 DLGAP5
CHPF2 P4HA1 HMCN1 STRA13 SMG5 FAM83D
MTFR1L TSPYL1 CROT PLPP1 PRKACB FSD1
REPIN1 MKLN1 CPS1 MDP1 ZWILCH ST6GAL1
MCL1 SRR FAM134A USP34 CEP41 MATN2
AQP1 PPL SON ARL14EP ACSS3 KLHL11
FAIM MCMBP COL1A1 MOCS3 SHC1 DPT
VCPIP1 TPM2 CLDN7 C18orf32 SAG POSTN
AKAP11 AMDHD2 AHCYL2 MASTL MAP3K2 COPZ2
ARFGEF3 HBA1,HBA2 S100P CCNYL1 RALGAPB ACTR1B
PIAS4 PFKFB3 FAM134C SDSL PPIC NR3C1
FYN SPAST MAP4K2 COQ3 CENPV HERC2
CDS2 TADA2B XPC MX1 PCSK9 SDPR
CEP131 FEM1A ACTG1 TNC ITPR3 GNPTG
SH3BGRL2 QSOX1 LSM4 FBXL18 SH3BP5L FARP2
ZIC5 PASK FLYWCH2 TMEM119 FAP AGTPBP1
ANKIB1 EDEM3 PANX1 CCDC28A DDX58 FOXK2
ERICH1 KIAA1211 ZMYM4 FN1 ARSA CSNK1E
MTRR NCOA3 PATZ1 UBE2S DDB2 CCDC68
POLG2 C10orf76 ADIRF CALD1 RALGAPA1 NUDT9
YAE1D1 C14orf142 TSPAN14 PTGIS FAM208A PANK1
TCN2 TAGLN ALG8 THAP11 NFIC TMEM165
BLOC1S6 FAM21A NCOR2 COL12A1 TGFBI CRELD1
MARH5 CNOT8 RANGRF MED16 CDA GULP1
WDR54 MET NOA1 PRKG1 CHMP1A SHARPIN
RRP8 TBC1D7 CPQ IFIT1 THBS1 HSDL2
GORAB TRAF6 AHDC1 DDX60 NDUFB6 ARHGEF6
CERCAM NPEPL1 GPR107 MAP3K15 MRS2 ELP3
TPM1 COMMD8 MED4 HACL1 IGFBP3 HTRA1
CD99L2 PEX16 GINS4 DSCR3 UBE2G1 EIF4EBP1
DYNC1I2 ACTN1 YPEL5 SMG6 ITGB4 PTGES
TPK1 REEP6 PMF1 PTBP2 IFIT2 PUM1
DYNC2H1 KDELR3 VIPAS39 KIF1B EMILIN2 CRIP2
HIGD2A C7orf26 DNM2 MMP2 KANK2 DHX30
RAP1B DNAJB5 MRPL33 SPANXA2-OT1 PIR SDCBP
HMGXB4 POLG FOXK1 PEX1 LGALS8 LAMC1
DNAH6 PDIA4 MTMR14 S100A14 CNTLN SLC25A32
TMED4 SPARC GBP1 CNN2 GCC1 CTHRC1
STAU2 SUPV3L1 DNAJC16 KIAA0430 CASP4 NID2
FAM69C TIMP2 OGFOD3 EED DCX PRNP
KCTD15 GSPT2 PCNT STARD4 OTUD7B PPP3CC
WDR35 CTSZ SLC15A4 BASP1 SLC44A1 AKR1C2
COA3 RAB2B GNA12 OPA3 INPP5A GAP43
CAAP1 VWA8 PALM KRT17 MIEF2 IKBKB
C1orf198 BUB1 ZBTB7A CD248 ACOX1 DNAJA4
CNN1 ANAPC4 LOX LAMA5 COL2A1 KRT6A
LRRC41 COL6A3 CABIN1 ECM1 MED8 KIF21A
NOL8 SLC30A5 COL16A1 TWISTNB GREM1 ICAM1
OSBPL11 TBC1D15 HORMAD2 EPHA2 MRPL51 B3GALT6
USP9Y VKORC1 ETNK1 MACF1 STAG3 SH3KBP1
BCAR1 KHDRBS3 TLE3 IGF2 STARD3NL CTDSPL2
FIBP RANBP10 IFT74 SERPINB2 SAMD9 FZD7
LGALS1 CSRP1 FBLN1 SERPINF1 SHCBP1 TUBG1
CAPN5 PTK7 PLAUR ZNF185 SGF29 RASA3
ACSF3 DNA2 PRSS23 PKP3 GDAP1 CAV2
FBXO2 CCND1 SLC34A3 KYNU RBM23 ACBD7
MAP2 MIC13 IFI44 PIK3CA KLC4 ODR4
GATC TANGO6 MITD1 ATL1 ANAPC13 SP100
MYL9 COL6A2 PPIL2 MPDZ CCBL1 TGM2
TGS1 CDYL KRT10 SNX32 OGN FMNL3
LAMB1 CSRP2 MON2 FAM127A WDR4 KRT14
BEND3 TRIM21 RPS6KA4 LENG8 SPRR3 FRG1
KLK14 CDC34 ASAP2 TAP2 NEXN INPP5B
TPM4 PPFIA1 KRT16 LIMK1 HOOK2 PPP2R2D
CPLX1 SUN1 WDR73 WWC3 SMG7 COL1A2
CCDC92 MYCL DESI2 FYCO1 RAC2 SEMA7A
TIMP3 PKD1L3 COL5A1 PYURF DPYSL4 SNX24
SERPINB8 FBXO3 RNF31 AKTIP BAZ2A UGGT2
HSPB1 CBX2 IFIT3 QPCTL C1orf50 CAV1
CD58 COL11A2 ISG15 RPL26L1 TYW3 CD44
PARP2 GOLT1B FOSL1 GRB7 CREG1 HOMER3
HSPB6 ABR NID1 ECT2 RAP2A NDRG1
COL5A2 AURKA GSDMD ENG WDR55 WNT5A
MRGBP EP300 MAU2 CHST14 GHDC NPHP3
FABP3 ANPEP ARHGDIB BST1 NABP2 SIRT5
DTX3L HAUS7 LTBP2 CLINT1 PXMP4 DPY19L1
ARL5A RNF113A CRBN GGA1 UBE2F GPNMB
NT5E CILP MROH2B SEPT5 ILF3 TANC1
STX3 NOTCH3 PLCG2 ARFIP1 NCOA5 QSOX2
SLC2A1 S100A6 CDCA5 CALHM2 KDM4B TIMELESS
F13A1 COMMD9 REN MECP2 TNXB ZYG11B
AHNAK2 RDH10 CLIC3 MME SLC39A14 GGCX
S100A4 ZCCHC6 CD9 CD82 LTBP1 STK11
UAP1L1 MED12 PXN GOSR2 B3GNT5 ABI3BP
ITGA2 OASL CTSK VAMP8
(ii) Proteins enriched more than two-fold in MYCL-WT compared with c-MYC-WT (EpiP)
IGFBP3 CLU CTHRC1 CDH13 CAVIN3 CCDC80
GLIPR2 GBP1 FLNA LAMB1 S100A6 COL5A2
CNN2 ITGA11 SH3BGRL3 CPQ PRSS23 LAMC1
NEGR1 LAMA5 IFIT2 LGALS1 HTRA1 TAGLN
TPM2 HSPB1 EHD2 VIM CAVIN1 CSRP1
TPM1 TGFBI S100A11 S100A4 COL5A1 NEXN
MOXD1 SLFN5 NME2P1 FNBP1 PLSCR3 ATPAF2
ZFYVE16 HSBP1 DGKA PLCD1 ABI3BP ANXA3
TCF3 PLCB4 SLC34A3 TMEM192 ADAMTSL1 ENDOD1
PTGES OSBPL9 LRRFIP1 GDPD2 CRYAB SETDB1
ST6GALNAC1 SMPD1 SETMAR SORBS3 B4GALT4 CHKB
RNF14 TNXB AHNAK2 DCTN3 PTBP2 EHBP1L1
TERF2IP ARMC8 PRC1 UQCC3 PTP4A2 TTYH3
MYCL BCAT2 ELN CRMP1 MX2 SGCE
HABP2 TXNIP RMND5A TIMP1 PITPNA DDX49
CHIC1 COL6A3 IMPACT RAB11B TMSB4X SNX7
DDR2 KRT5 PLEKHO2 SMTN LIPG RGS3
GREM1 COL5A1 HNRNPDL LMOD1 MAP4K4 PPP3CB
QTRT2 ARID1A KRT17 SELENOM CYP1B1 CD151
MT1X CTNNA2 KRT6A MBD5 RAP1B R3HCC1
VPS37A STAM2 CTSL ITGA1 PAIP1 DHRS4
MTPAP CDK2
Bold value: p < 0.05
(iii) Proteins enriched more than two-fold in c-MYC-ΔMB0 compared with c-MYC-WT (EpiP)
ITGA1 PSMF1 FNBP1 BCAT2 DGKA YIPF3
MBD5 KRT5 S100A6 MOXD1 RMND5A PPIL3
TAP1 PAIP2 OXR1 MMP2 SCLY TBC1D10B
CYP1B1 PPDPF TPM1 PLSCR3 SEMA7A PPP3CB
RNF115 TMEM192 IGFBP3 MBD2 RBM6 ITPRIP
SPIRE2 OSBPL9 TPM2 TERF2IP DIP2B RAB11B
EDC3 SMPD1 DHRS4 LMOD1 OS9 CPQ
COG3 KRT6A HSBP1 LRRFIP1 CHCHD6 FNTB
CD151 EXOC6B MROH1 COL6A3 AHNAK2 BCL2L13
RPS6KC1 NCOR2 UQCC3 SELENOM COG4 DNAJC17
PRC1 CDK2 INTS1 ATPAF2 ENDOD1 STK10
DUSP23 PTGES CCDC50 TIMP1 TRIM56 YAP1
CHIC1 EHBP1L1 OLFML3 CLU RAC2 EHD2
SDC1 DNAJC19 CTNNA2 CDH13 ITPA PITPNA
SNAPIN PTPN14 LEMD3 SEC24A CCDC9 MROH9
PAIP1 ANXA3 BAG3 MAP3K20 ELN NEXN
STAM2 IMPACT ZFYVE16 TNXB RMDN2 CRMP1
HABP2 TIMP2 MYO1D TRAPPC2L LAMA5 CWC22
DLGAP4 TANC1 DCTN3 CAVIN3 PPIP5K2 LMAN2L
ELP4 SRSF4 KRT17 IFIT2 ERI1 EEF1AKNMT
SMTN NEGR1 HNRNPDL ARID1A PARP12 SCRN3
WDR4 UBAP1 SLFN5 NCOA5 PHRF1 SPARC
CAV1 KRT16 ERCC2 MYO1C L2HGDH LPCAT3
ITGA11 NELFA PXDC1 IL12RB2 EIPR1 DPP7
MCAM COG1 POLR3C HSPB1 CAVIN1 GLIPR2
PIKFYVE C1orf198 SCPEP1 PALM NKRF CNN1
RHOB CUL4B CCDC80 ARL2BP GNG12 BMP1
STIM1 VKORC1 CERCAM CFAP74 ERGIC3 S100A4
TAGLN MRPS6 KIF4A P3H4 ALKBH4 PTP4A2
ELMO2 CRYAB SLC27A1 MAEA GRB10 THY1
AP1S2 ZNF579 SLC33A1
(iv) Commonly enriched proteins in (i) and (ii) and (iii)
KRT6A
PTGES
S100A6
TPM1
IGFBP3
TPM2
KRT17
COL6A3
TNXB
IFIT2
AHNAK2
LAMA5
CPQ
NEXN
TAGLN
HSPB1
GLIPR2
S100A4

Four groups are described: (i) proteins whose peptide counts increased more than two-fold in MYCL-WT/HDFs compared with c-MYC-WT/HDFs using SeV on day 3, 5, or 7; (ii) proteins whose peptide counts increased more than two-fold in MYCL-WT compared with c-MYC-WT using EpiP; (iii) proteins whose peptide counts increased more than two-fold in c-MYC-ΔMB0 compared with c-MYC-WT using EpiP; and (iv) commonly identified proteins. Bold fonts in the group (ii) indicate identified proteins with p < 0.05 (two-sample paired t-test). n = 3 for EpiP reprogramming.

Table 2.

MS analysis of identified proteins in cells reprogrammed with c-MYC.

(i) Proteins enriched more than two-fold in c-MYC-WT compared with MYCL-WT (SeV)
ATXN7L3B TIMM21 SLC2A3 CA14 CRLF3 SYT6
TMEM161A MTM1 METTL15 NKAP CDS2 MRS2
MARS2 ERCC2 TDP1 MFAP4 ANAPC16 CARS2
NOLC1 IGHMBP2 MRPL34 FECH PARP2 ING1
ADNP2 STEAP3 AK6 PDZD8 EPB41L5 PEX16
ZER1 CKS1B GGPS1 DBNDD1 MIEF1 FUCA1
ADSSL1 POTEJ TMEM209 CCNL2 TOP3A ULK1
MGA FAM162A AMMECR1 ISG20L2 CEP78 NOM1
PAPD4 PROCR IFRD2 LRRC41 UBR3 PHF3
RIN1 SPPL2B ARAF DNM2 HPS5 PSEN1
PARD3 ARHGEF16 RHPN2 PRPF18 SEMA4C RPUSD3
NYNRIN ARHGEF7 VRTN PHF10 DMD RPL26L1
RANBP6 CNOT4 TSPYL5 CDC25C REEP4 FADD
INPP5F ZBTB7A GPN3 RBPMS2 BRAF ORC6
CACNA2D2 AP1B1 NCAPD3 RRP8 MASTL POLR2M
CASC3 NCL C1orf174 LRRC14 SLC27A3 ACSF3
DHRS11 RBM23 WDR55 CAMK4 NDRG3 ALS2
NOVA1 SOX3 CLCN7 EHMT1 C7orf26 NSUN5
NMRAL1 STK25 NFKB2 OSBPL1A VPS37B RAD23A
HS2ST1 LYAR PHKA1 SDC4 MGST2 SNTB1
MEN1 WDR4 DDX28 C1orf198 AKAP9 COQ9
STYX PHF5A PCDH1 TMSB4X AP1G2 MYO1G
UCKL1 APC TBC1D15 FASTKD1 APCDD1L MARH5
ULK3 LONP2 SETD1A ETFDH ANKS1A LRP8
PALD1 ANAPC5 CARMIL1 GATM PANX1 NME3
UBA52 ZNF806 NCOR2 DVL2 CTDP1 PHKB
GINS3 DNPH1 CDCA5 BCKDK TTF1 TGFBRAP1
HAUS2 HMGCR SNCA KLHDC4 TBP AP1M2
E2F4 AFAP1L1 ZMYM6NB N4BP2 TRIT1 CCDC134
ATL1 INTS6 CHD8 SPINT2 RASA2 NCK2
MAL2 ATAD3A SLC25A32 LSAMP ACOT8 KIFAP3
JARID2 CLSTN1 USP36 PTGIS PIAS4 TMEM41B
SEC14L1 TUBGCP4 GEMIN8 VWA9 RPP25L NRBP2
DOLPP1 WARS2 PLEKHA6 MRGBP ZCCHC6 ZFP36L1
SLC4A7 SCARB1 ARID1B PMF1 XXYLT1 ANKRD50
MT-CO1 MET RBM47 LIN28B EXD2 GORAB
GCSH PLTP PRKAB1 CUTC SDSL FARS2
LRRC8E ARHGAP12 FBXW9 PMS2 NAA30 STRA13
FASTKD5 ZCCHC10 TTK BNC2 COX16 BCS1L
NDE1 STX3 LARP1B PTCD1 TPD52 SMG1
ACBD7 TRIP12 PTPMT1 ASB3 MTG1 ANKRD12
STK33 HEXIM1 RBM45 ATG9A ANKIB1 B3GALNT2
C12orf43 SLC25A15 NDUFAF5 BAG4 NOA1 SFRP2
VPRBP FOXK1 GPM6B POLE TRADD AMFR
RPS6KA1 PLA2G4A SELO PROM1 CHTF18 BOD1
SPC24 KAT7 RAB17 IGFBP6 PNPLA4 AGTRAP
UBE2Q1 HIGD2A RAPH1 SDF2 ARHGAP4 ODR4
MRPS18C QSOX1 COX17 CHUK RAPGEF2 GINS1
DFFA CENPV PTPN9 FUT11 ERMP1 SOGA1
DHX32 GEMIN6 HDHD2 GLE1 PTPRZ1 CREG1
GATC PDXP MID1 WRAP53 POU2F1 CA2
APPL1 TMEM14C TXNIP SLC7A3 FABP6 ITGA2
CWC22 MPDZ PIGG ACTB INCENP CARNMT1
RHBDD2 MRPL38 PUM1 HPDL NME4 CDKN2A
TRIM27 ARHGEF10L BDH1 CDC26 CTU1 ATF7
HMGXB4 L3MBTL3 MAP1LC3A ISLR URB1 MRPL21
CAMK1 RILPL1 WDR37 IGF2BP1 NAPEPLD DPH6
FCF1 ANKRD29 ANAPC13 CD3EAP WDR89 SLC25A17
DNA2 CENPM CEP170B GCA CSTF2T NKRF
SLC35A2 PMS1 SLC5A6 COQ5 SPR RBM15B
USP19 LAMA4 DNM1L INTS2 BCAS3 KIF22
NHEJ1 RPP40 TNC SPNS1 RPRD1A DDB2
IFIT5 ARMCX1 FAT1 DAP BMPR1A NPHP3
ARID3A MRPL13 ZBED1 GTF2H1 PATZ1 DPH2
C11orf98 RRP7A AKAP1 ANAPC1 NUDT16 CD74
DCAKD ASB6 DNMBP UTP11L TUBG1 HAUS7
GAA PDK1 DOHH ISYNA1 BRMS1 EXOC6
ARAP3 CHKB NOL8 DDX52 ORC5 COA7
NAA40 IQSEC1 TRIM24 DNTTIP1 HEATR6 SH3BP4
ZMYM3 MED30 CLASP2 PRPF38B TMEM256 GTF3C2
MRPL10 NDUFAF7 VCPIP1 HSPB11 CASP7 TOR1B
ITPR2 PRPF39 GCFC2 KIF21A DPPA4 TIMM8B
GTF2H4 MRPL16 BAZ1A EXOC6B MRPL41 POLR3B
USP9Y SYNE2 MID1IP1 MOCS2 METTL5 PRUNE
UBE2V2 CDH1 GJA1 CHMP6 RCC1 RAPGEF6
COMMD9 HMBS SQLE IGFBP2 DIAPH2 EPB41
HIST1H1E MAP3K4 CDK18 ARL15 UQCC1 HTATIP2
PTDSS2 TATDN2 MTA1 SNX18 EIF1B MAEA
SCAF1 UBE2J2 NUP37 BAG1 TSSC4 RCOR2
FAM213A MFF TTLL12 UBXN6 EFEMP2 ZZEF1
NFYB PDS5B FXN AGPAT5 ARFGEF2 TCOF1
SCAF11 RAPGEF1 PARG PRIM1 USF1 L1TD1
SEPHS1 BRD8 POP7 EXT2 TSEN34 CAMKV
SLC29A1 MBD3 PPIF MTX3 COG1 FASTKD2
ARL14EP MRPL40 CD320 MBD1 VARS2 BRD3
MRPS18B ACY1 PPIE RIF1 VPS8 POGZ
RSL1D1 PAK1 STRBP TERF2 TOP2A SLC39A10
QRICH1 CISD1 POLB DHX37 TRMT5 TIMMDC1
TRABD SON SET LYST RNASEH2B MVK
ZC3HC1 NDUFC1 HSPA4L EXOSC1 TCEANC2 NASP
CYP2S1 NSMCE3 HPRT1 HUS1 PRRC2A RDH13
KANK1 PHF14 RBM7 SIRT5 QPCTL CROCC
LIMK2 CWF19L1 KIF1B VPS39 CHD7 YPEL5
SLC7A5 VPS25 LRWD1 FPGS NT5C3A NCKIPSD
PSIP1 CELF2 MDC1 ANP32A ACADSB GPC4
TUBB4A BOP1 NT5C CTSC ANKLE2 ORC4
UTP18 CHST14 NUS1 PLK1 GPKOW SIKE1
ADAM15 NUDCD2 SSU72 NFYC LIG1 MSH2
HNRNPR MSI2 STK26 EBP ITPK1 STAU2
URI1 SLC7A8 MANBAL RNGTT PRIM2 SEC24B
MRPS34 RMND5A F11R SCAF8 RPAP1 SPATA5L1
RCC2 POLRMT SERF2 TMEM115 PARP1 C2CD5
BEND3 BRAT1 TERF2IP MT-ND2 FAM136A NOP2
ARL5B GFM2 WDR3 AARSD1 PPID HRSP12
CHD2 MRPL45 YTHDF1 THEMIS INTS4 PLEKHA1
CBX3 SIRT7 CENPF CAMSAP2 MCC PTPN2
NANOG SLBP MCAT MRPL24 MZT1 ANAPC4
HIST1H1A KPNA2 MED14 NDUFB9 NEFL DUS3L
HSP90AA4P CMSS1 ZNF706 PTRHD1 PBRM1 ABI3BP
MED10 PFAS BRIX1 QRSL1 THNSL1 ADRM1
CECR2 NCOA5 ABRACL WIPF2 USP28 GEMIN4
CHD1 SBNO1 LSM12 COG2 TARS2 KIF11
CHD1L MLH1 MNAT1 DDX47 SRPK1 NACAP1
XPC NELFCD MPP6 HAUS6 TANC1 PPAN
MRPL33 PUM2 MRPL15 FAM65A ERI3 TOM1L2
TIMM13 SPRYD4 MICU1 HMGN5 XPO4 WDR43
DDX20 YTHDC2 SLC25A22 CACUL1 PCF11 PRC1
DNAAF2 ACAT1 RWDD4 DHPS PFKM NUDT16L1
MTMR2 GPN1 SMARCA4 EI24 SCFD2 PPP3CB
RNASEH2A GTF2E2 SMARCD1 ADCK3 TRMT1 RABEP1
CD97 GLT8D1 UBR5 HLTF TXNRD2 TDP2
CCNY NCAPD2 USP48 LRCH2 UBQLN1 TRIP10
MCM3 HSPA14 ZBTB8OS MAP2K7 APOBEC3C TTC27
DYSF MINA BAK1 HERC2 POLG2 TRAP1
EXOSC7 RCL1 C17orf62 PUS7 CASP6 ISOC1
THYN1 MYL6 CBR4 RFC3 SRSF10 LCLAT1
HIBADH UHRF1 DHX57 MCM6 UBL4A MRPS17
TFRC GALK2 MKI67 CEBPZ CHRAC1 TTC4
METTL3 GSTZ1 UBE2O LRSAM1 NSA2 AGPAT4
MRPS5 MAP3K7 ZNF330 MLLT11 HK2 BLMH
PCCA LYPLAL1 CPSF2 PEX3 INPP4A SORD
SLC35F2 MRPL23 GNL3 WBP11 SAP30 INPPL1
TBC1D9B MRPS31 GMPS IMPDH2 SSRP1 LBR
TRIM28 NELFB LDAH DDX21 TWSG1 RBMX
NDUFAF1 PHF6 TFB2M EBNA1BP2 ZMYM2 MLYCD
UROD PKP3 NUBP2 FANCI ARIH2 ZNF22
USP11 ARFRP1 PKN1 FAR1 MYBBP1A PDS5A
CHMP7 COASY SAP18 GTF3C4 SMARCAD1 DNAAF5
CTAGE5 GART UBE2I MRPL27 ENY2 PDK3
RUVBL1 PEAK1 WDR6 MYEF2 PWP2 RPA2
EXOSC4 FRA10AC1 ADAD2 NARS2 FAM64A XRCC4
GTF2E1 DDX51 BMS1 OGFR MRPL3 CHAC2
PES1 IGF2BP3 LDHB ORC3 MSH6 DPYSL5
HEATR1 KATNA1 PTMA SLC52A2 NLE1 MCM7
POLD1 MCM2 CXorf56 SMAD5 GPATCH4 STOML2
FLVCR1 MYH14 DAXX ZCCHC8 TAMM41 TOMM34
LGALS3BP PARN KIF1BP C5orf22 TP53RK NACC1
MRPS30 TKT ELAC2 PRKCI PDCD11 DNAJB4
MTMR12 SUPV3L1 DARS2 RAVER1 SIGMAR1 DHODH
SLC3A2 BTAF1 HSDL1 EIF3C TBPL1 NOC2L
MRPS28 CADM1 MRPL37 SRI BZW2 NDUFC2
PCCB DNTTIP2 PCBD2 TRIM2 CPSF1 RABGGTB
RFC5 ECT2 AGTPBP1 TRIM22 ECM29 PANK4
C11orf73 MCAM THUMPD1 WDR18 RNPS1 SCO1
TIMM17B INTS8 TUSC3 DCAF16 GTF2A1 SIRT1
UTP6 MRPL11 XRN1 DCTPP1 HSPBP1 TUFM
WDR92 PIR ACAA2 DNAJC2 NPM3 ADNP
CERS6 NUDT12 APTX DSG2 NTHL1 BOLA3
DDX24 NUP35 ATL2 NOL11 DDX31 ATPAF1
GCDH RCHY1 C12orf10 HIP1R PRPS2 MCM5
WDR75 RHOT1 KIAA1211 DDX54 RSPRY1 CDC123
NOP16 TACO1 GLMN HOOK1 WNK1 NUP155
POLR1A TBL3 GNAI1 KIAA2013 C7orf50 GUSB
GUF1 TIMM17A GRWD1 LBH CCNK ILKAP
SMYD5 AGL POR LIG3 CMTR1 LRBA
WDR5 TOMM5 ARL8A PCK2 PDCD4 NAT10
ACO1 TSC2 GNL3L MTFP1 ABT1 KEAP1
ANKRD28 UBTF STK3 SCAP PPAT PSAT1
APOA1BP WDR54 SYT1 SCRIB PTBP3 RNASEH2C
APOO ASF1A GSPT2 SDHB SUPT16H DBR1
PSME3 PPWD1 UBQLN4 CHAF1A TRMT10C SACS
BYSL CDH13 USP24 ARID1A GJB2 TEX10
UBA2 CLUH ARL2 AS3MT ABCC1 MRPL57
DDX56 EIF2D ATP1B3 DCAF8 AGK AIF1L
RBM42 FEN1 CCDC12 ELOVL6 EFNB1 NCAPG2
SARS2 OSBPL2 CDCA8 GNA13 ATF7IP CCDC50
ADI1 HAUS8 C1orf131 GOLM1 DEK DTD1
MCL1 INTS1 AHCY GYS1 PAICS DTWD1
CCDC59 MAK16 RUVBL2 ISY1 ECT2L GTPBP10
ZNF593 RBM26 FDXR MRI1 HS1BP3 LSM6
DNAJC8 SALL4 AATF LETM1 LAS1L MRPS11
SMARCA5 TMPO LTA4H MYCBP MRPL19 NEPRO
PCBP2 WBSCR22 CCNH DLGAP5 NDUFS7 NOP58
HDAC2 WDR48 GLTSCR2 PELP1 HARS2 NT5DC1
HIST1H1B TOX4 TPI1 LUC7L ATP11C NXF1
HNRNPC VRK1 KDM2A COMMD8 CACNA2D1 RAD21
HNRNPU WIPI1 USP39 SSB CDCA7L SNF8
LARS ASH2L VPS36 ZNF346 CRNKL1 TELO2
LRRC57 AASDHPPT CNPY3 GLUL CWC27 TNPO3
CHORDC1 CKAP2 CXADR ILF2 PEG10 TTI2
MANBA DCAF13 PLS1 LVRN C1QBP UBE2A
MEMO1 EIF4A3 EXTL2 MED24 GLYR1 UBXN1
MRPS18A EIF5B NIFK POLR2H HMOX2 ABCB6
NDUFB4 FNBP1L NOL10 KIF5C EXOSC9 ATP2B1
TOMM40 RBM28 GSTP1 TATDN1 FTSJ3 DAGLB
PLCG1 IFI16 HSPA4 TMEM192 MPI SMPD4
POLE4 KDM1A NUP188 TSFM DLAT FAM210A
POLR2D NOL6 PRPF40A UBAP2 MSTO1 GTF2I
SHPK NUP133 RBM12B DAB2IP SAFB LARP1
SPCS1 PDHA1 STX18 PPFIA1 NUP50 METTL13
SAAL1 QTRTD1 SUPT6H ADSL QSER1 POLR3C
TRMT1L ASUN BMP1 AFG3L2 GEMIN5 NEU1
PEX6 HDAC3 NDC80 MRRF HMGN1 TIMM44
REEP6 OTX2 LPCAT1 MTPAP SNU13 UMPS
TRIAP1 TUT1 GRSF1 NAA20 ACSS3 NCK1
ERBB2 CCDC28B XRN2 NDUFAF4 MIF PPP2R5A
SGSH CRADD MT-ND4 GATAD2A MRPL9 RAD50
OSGEPL1 ADGRL2 MTUS2 NRBF2 FAM192A DNPEP
THAP11 HEATR5B RABGEF1 POP1 HEATR3 SRRM2
CACTIN PRKD1 MRPL50 PRMT1 NIPBL STK4
SLC25A35 ECE2 RPL13A SDCBP NTMT1 TBRG4
ZFAND6 DSEL SDAD1 RPL21 PDCD5 PPIG
RALGAPB MYO5C TRMT6 RBM39 GULP1 DCP1A
IGSF1 POLG UBE3A SLC30A1 RFC4 TUBAL3
MGRN1 TPK1 KCTD10 SMAP ACIN1 UBXN7
TMEM41A DNAL1 F8A1,F8A2,F8A3 TKFC BSG ARHGEF40
FBP1 FBXL6 DFFB TRIM33 EHBP1 ATP5S
CDC20 PLEKHA7 WDR73 CD70 EMC3 SLC9A3R1
COBLL1 TRIM9 SP1 YARS2 RBM19 CKMT1A,CKMT1B
HSP90AB3P MRPL35 CCNA2 HDDC2 KDM3B PPA1
SMARCAL1 MALSU1 AURKB PPM1G EARS2 HSP90AA1
SH3GL3 MPHOSPH6 NACC2 HMGB2 GTPBP4 ABCB10
CYP2U1 BSDC1 TLK1 LEO1 MFAP1 GIT1
FLCN TYRO3 SH3PXD2A EMC4 CPS1 INTS9
IRS2 SIRT3 FUT8 CDK2 TNFAIP6 SDHAF4
KITLG ALDH3A1 GPR180 CFAP36 ANK3 CBX2
RBBP9 EML2 POLR3GL FN3K VWA5A RAVER2
ATXN7L3B TIMM21 SLC2A3 CA14 CRLF3 SYT6
TMEM161A MTM1 METTL15 NKAP CDS2 MRS2
MARS2 ERCC2 TDP1 MFAP4 ANAPC16 CARS2
NOLC1 IGHMBP2 MRPL34 FECH PARP2 ING1
ADNP2 STEAP3 AK6 PDZD8 EPB41L5 PEX16
ZER1 CKS1B GGPS1 DBNDD1 MIEF1 FUCA1
ADSSL1 POTEJ TMEM209 CCNL2 TOP3A ULK1
MGA FAM162A AMMECR1 ISG20L2 CEP78 NOM1
PAPD4 PROCR IFRD2 LRRC41 UBR3 PHF3
RIN1 SPPL2B ARAF DNM2 HPS5 PSEN1
PARD3 ARHGEF16 RHPN2 PRPF18 SEMA4C RPUSD3
NYNRIN ARHGEF7 VRTN PHF10 DMD RPL26L1
RANBP6 CNOT4 TSPYL5 CDC25C REEP4 FADD
INPP5F ZBTB7A GPN3 RBPMS2 BRAF ORC6
CACNA2D2 AP1B1 NCAPD3 RRP8 MASTL POLR2M
CASC3 NCL C1orf174 LRRC14 SLC27A3 ACSF3
DHRS11 RBM23 WDR55 CAMK4 NDRG3 ALS2
NOVA1 SOX3 CLCN7 EHMT1 C7orf26 NSUN5
NMRAL1 STK25 NFKB2 OSBPL1A VPS37B RAD23A
HS2ST1 LYAR PHKA1 SDC4 MGST2 SNTB1
MEN1 WDR4 DDX28 C1orf198 AKAP9 COQ9
STYX PHF5A PCDH1 TMSB4X AP1G2 MYO1G
UCKL1 APC TBC1D15 FASTKD1 APCDD1L MARH5
ULK3 LONP2 SETD1A ETFDH ANKS1A LRP8
PALD1 ANAPC5 CARMIL1 GATM PANX1 NME3
UBA52 ZNF806 NCOR2 DVL2 CTDP1 PHKB
GINS3 DNPH1 CDCA5 BCKDK TTF1 TGFBRAP1
HAUS2 HMGCR SNCA KLHDC4 TBP AP1M2
E2F4 AFAP1L1 ZMYM6NB N4BP2 TRIT1 CCDC134
ATL1 INTS6 CHD8 SPINT2 RASA2 NCK2
MAL2 ATAD3A SLC25A32 LSAMP ACOT8 KIFAP3
JARID2 CLSTN1 USP36 PTGIS PIAS4 TMEM41B
SEC14L1 TUBGCP4 GEMIN8 VWA9 RPP25L NRBP2
DOLPP1 WARS2 PLEKHA6 MRGBP ZCCHC6 ZFP36L1
SLC4A7 SCARB1 ARID1B PMF1 XXYLT1 ANKRD50
MT-CO1 MET RBM47 LIN28B EXD2 GORAB
GCSH PLTP PRKAB1 CUTC SDSL FARS2
LRRC8E ARHGAP12 FBXW9 PMS2 NAA30 STRA13
FASTKD5 ZCCHC10 TTK BNC2 COX16 BCS1L
NDE1 STX3 LARP1B PTCD1 TPD52 SMG1
ACBD7 TRIP12 PTPMT1 ASB3 MTG1 ANKRD12
STK33 HEXIM1 RBM45 ATG9A ANKIB1 B3GALNT2
C12orf43 SLC25A15 NDUFAF5 BAG4 NOA1 SFRP2
VPRBP FOXK1 GPM6B POLE TRADD AMFR
RPS6KA1 PLA2G4A SELO PROM1 CHTF18 BOD1
SPC24 KAT7 RAB17 IGFBP6 PNPLA4 AGTRAP
UBE2Q1 HIGD2A RAPH1 SDF2 ARHGAP4 ODR4
MRPS18C QSOX1 COX17 CHUK RAPGEF2 GINS1
DFFA CENPV PTPN9 FUT11 ERMP1 SOGA1
DHX32 GEMIN6 HDHD2 GLE1 PTPRZ1 CREG1
GATC PDXP MID1 WRAP53 POU2F1 CA2
APPL1 TMEM14C TXNIP SLC7A3 FABP6 ITGA2
CWC22 MPDZ PIGG ACTB INCENP CARNMT1
RHBDD2 MRPL38 PUM1 HPDL NME4 CDKN2A
TRIM27 ARHGEF10L BDH1 CDC26 CTU1 ATF7
HMGXB4 L3MBTL3 MAP1LC3A ISLR URB1 MRPL21
CAMK1 RILPL1 WDR37 IGF2BP1 NAPEPLD DPH6
FCF1 ANKRD29 ANAPC13 CD3EAP WDR89 SLC25A17
DNA2 CENPM CEP170B GCA CSTF2T NKRF
SLC35A2 PMS1 SLC5A6 COQ5 SPR RBM15B
USP19 LAMA4 DNM1L INTS2 BCAS3 KIF22
NHEJ1 RPP40 TNC SPNS1 RPRD1A DDB2
IFIT5 ARMCX1 FAT1 DAP BMPR1A NPHP3
ARID3A MRPL13 ZBED1 GTF2H1 PATZ1 DPH2
C11orf98 RRP7A AKAP1 ANAPC1 NUDT16 CD74
DCAKD ASB6 DNMBP UTP11L TUBG1 HAUS7
GAA PDK1 DOHH ISYNA1 BRMS1 EXOC6
ARAP3 CHKB NOL8 DDX52 ORC5 COA7
NAA40 IQSEC1 TRIM24 DNTTIP1 HEATR6 SH3BP4
ZMYM3 MED30 CLASP2 PRPF38B TMEM256 GTF3C2
MRPL10 NDUFAF7 VCPIP1 HSPB11 CASP7 TOR1B
ITPR2 PRPF39 GCFC2 KIF21A DPPA4 TIMM8B
GTF2H4 MRPL16 BAZ1A EXOC6B MRPL41 POLR3B
USP9Y SYNE2 MID1IP1 MOCS2 METTL5 PRUNE
UBE2V2 CDH1 GJA1 CHMP6 RCC1 RAPGEF6
COMMD9 HMBS SQLE IGFBP2 DIAPH2 EPB41
HIST1H1E MAP3K4 CDK18 ARL15 UQCC1 HTATIP2
PTDSS2 TATDN2 MTA1 SNX18 EIF1B MAEA
SCAF1 UBE2J2 NUP37 BAG1 TSSC4 RCOR2
FAM213A MFF TTLL12 UBXN6 EFEMP2 ZZEF1
NFYB PDS5B FXN AGPAT5 ARFGEF2 TCOF1
SCAF11 RAPGEF1 PARG PRIM1 USF1 L1TD1
SEPHS1 BRD8 POP7 EXT2 TSEN34 CAMKV
SLC29A1 MBD3 PPIF MTX3 COG1 FASTKD2
ARL14EP MRPL40 CD320 MBD1 VARS2 BRD3
MRPS18B ACY1 PPIE RIF1 VPS8 POGZ
RSL1D1 PAK1 STRBP TERF2 TOP2A SLC39A10
QRICH1 CISD1 POLB DHX37 TRMT5 TIMMDC1
TRABD SON SET LYST RNASEH2B MVK
ZC3HC1 NDUFC1 HSPA4L EXOSC1 TCEANC2 NASP
CYP2S1 NSMCE3 HPRT1 HUS1 PRRC2A RDH13
KANK1 PHF14 RBM7 SIRT5 QPCTL CROCC
LIMK2 CWF19L1 KIF1B VPS39 CHD7 YPEL5
SLC7A5 VPS25 LRWD1 FPGS NT5C3A NCKIPSD
PSIP1 CELF2 MDC1 ANP32A ACADSB GPC4
TUBB4A BOP1 NT5C CTSC ANKLE2 ORC4
UTP18 CHST14 NUS1 PLK1 GPKOW SIKE1
ADAM15 NUDCD2 SSU72 NFYC LIG1 MSH2
HNRNPR MSI2 STK26 EBP ITPK1 STAU2
URI1 SLC7A8 MANBAL RNGTT PRIM2 SEC24B
MRPS34 RMND5A F11R SCAF8 RPAP1 SPATA5L1
RCC2 POLRMT SERF2 TMEM115 PARP1 C2CD5
BEND3 BRAT1 TERF2IP MT-ND2 FAM136A NOP2
ARL5B GFM2 WDR3 AARSD1 PPID HRSP12
CHD2 MRPL45 YTHDF1 THEMIS INTS4 PLEKHA1
CBX3 SIRT7 CENPF CAMSAP2 MCC PTPN2
NANOG SLBP MCAT MRPL24 MZT1 ANAPC4
HIST1H1A KPNA2 MED14 NDUFB9 NEFL DUS3L
HSP90AA4P CMSS1 ZNF706 PTRHD1 PBRM1 ABI3BP
MED10 PFAS BRIX1 QRSL1 THNSL1 ADRM1
CECR2 NCOA5 ABRACL WIPF2 USP28 GEMIN4
CHD1 SBNO1 LSM12 COG2 TARS2 KIF11
CHD1L MLH1 MNAT1 DDX47 SRPK1 NACAP1
XPC NELFCD MPP6 HAUS6 TANC1 PPAN
MRPL33 PUM2 MRPL15 FAM65A ERI3 TOM1L2
TIMM13 SPRYD4 MICU1 HMGN5 XPO4 WDR43
DDX20 YTHDC2 SLC25A22 CACUL1 PCF11 PRC1
DNAAF2 ACAT1 RWDD4 DHPS PFKM NUDT16L1
MTMR2 GPN1 SMARCA4 EI24 SCFD2 PPP3CB
RNASEH2A GTF2E2 SMARCD1 ADCK3 TRMT1 RABEP1
CD97 GLT8D1 UBR5 HLTF TXNRD2 TDP2
CCNY NCAPD2 USP48 LRCH2 UBQLN1 TRIP10
MCM3 HSPA14 ZBTB8OS MAP2K7 APOBEC3C TTC27
DYSF MINA BAK1 HERC2 POLG2 TRAP1
EXOSC7 RCL1 C17orf62 PUS7 CASP6 ISOC1
THYN1 MYL6 CBR4 RFC3 SRSF10 LCLAT1
HIBADH UHRF1 DHX57 MCM6 UBL4A MRPS17
TFRC GALK2 MKI67 CEBPZ CHRAC1 TTC4
METTL3 GSTZ1 UBE2O LRSAM1 NSA2 AGPAT4
MRPS5 MAP3K7 ZNF330 MLLT11 HK2 BLMH
PCCA LYPLAL1 CPSF2 PEX3 INPP4A SORD
SLC35F2 MRPL23 GNL3 WBP11 SAP30 INPPL1
TBC1D9B MRPS31 GMPS IMPDH2 SSRP1 LBR
TRIM28 NELFB LDAH DDX21 TWSG1 RBMX
NDUFAF1 PHF6 TFB2M EBNA1BP2 ZMYM2 MLYCD
UROD PKP3 NUBP2 FANCI ARIH2 ZNF22
USP11 ARFRP1 PKN1 FAR1 MYBBP1A PDS5A
CHMP7 COASY SAP18 GTF3C4 SMARCAD1 DNAAF5
CTAGE5 GART UBE2I MRPL27 ENY2 PDK3
RUVBL1 PEAK1 WDR6 MYEF2 PWP2 RPA2
EXOSC4 FRA10AC1 ADAD2 NARS2 FAM64A XRCC4
GTF2E1 DDX51 BMS1 OGFR MRPL3 CHAC2
PES1 IGF2BP3 LDHB ORC3 MSH6 DPYSL5
HEATR1 KATNA1 PTMA SLC52A2 NLE1 MCM7
POLD1 MCM2 CXorf56 SMAD5 GPATCH4 STOML2
FLVCR1 MYH14 DAXX ZCCHC8 TAMM41 TOMM34
LGALS3BP PARN KIF1BP C5orf22 TP53RK NACC1
MRPS30 TKT ELAC2 PRKCI PDCD11 DNAJB4
MTMR12 SUPV3L1 DARS2 RAVER1 SIGMAR1 DHODH
SLC3A2 BTAF1 HSDL1 EIF3C TBPL1 NOC2L
MRPS28 CADM1 MRPL37 SRI BZW2 NDUFC2
PCCB DNTTIP2 PCBD2 TRIM2 CPSF1 RABGGTB
RFC5 ECT2 AGTPBP1 TRIM22 ECM29 PANK4
C11orf73 MCAM THUMPD1 WDR18 RNPS1 SCO1
TIMM17B INTS8 TUSC3 DCAF16 GTF2A1 SIRT1
UTP6 MRPL11 XRN1 DCTPP1 HSPBP1 TUFM
WDR92 PIR ACAA2 DNAJC2 NPM3 ADNP
CERS6 NUDT12 APTX DSG2 NTHL1 BOLA3
DDX24 NUP35 ATL2 NOL11 DDX31 ATPAF1
GCDH RCHY1 C12orf10 HIP1R PRPS2 MCM5
WDR75 RHOT1 KIAA1211 DDX54 RSPRY1 CDC123
NOP16 TACO1 GLMN HOOK1 WNK1 NUP155
POLR1A TBL3 GNAI1 KIAA2013 C7orf50 GUSB
GUF1 TIMM17A GRWD1 LBH CCNK ILKAP
SMYD5 AGL POR LIG3 CMTR1 LRBA
WDR5 TOMM5 ARL8A PCK2 PDCD4 NAT10
ACO1 TSC2 GNL3L MTFP1 ABT1 KEAP1
ANKRD28 UBTF STK3 SCAP PPAT PSAT1
APOA1BP WDR54 SYT1 SCRIB PTBP3 RNASEH2C
APOO ASF1A GSPT2 SDHB SUPT16H DBR1
PSME3 PPWD1 UBQLN4 CHAF1A TRMT10C SACS
BYSL CDH13 USP24 ARID1A GJB2 TEX10
UBA2 CLUH ARL2 AS3MT ABCC1 MRPL57
DDX56 EIF2D ATP1B3 DCAF8 AGK AIF1L
RBM42 FEN1 CCDC12 ELOVL6 EFNB1 NCAPG2
SARS2 OSBPL2 CDCA8 GNA13 ATF7IP CCDC50
ADI1 HAUS8 C1orf131 GOLM1 DEK DTD1
MCL1 INTS1 AHCY GYS1 PAICS DTWD1
CCDC59 MAK16 RUVBL2 ISY1 ECT2L GTPBP10
ZNF593 RBM26 FDXR MRI1 HS1BP3 LSM6
DNAJC8 SALL4 AATF LETM1 LAS1L MRPS11
SMARCA5 TMPO LTA4H MYCBP MRPL19 NEPRO
PCBP2 WBSCR22 CCNH DLGAP5 NDUFS7 NOP58
HDAC2 WDR48 GLTSCR2 PELP1 HARS2 NT5DC1
HIST1H1B TOX4 TPI1 LUC7L ATP11C NXF1
HNRNPC VRK1 KDM2A COMMD8 CACNA2D1 RAD21
HNRNPU WIPI1 USP39 SSB CDCA7L SNF8
LARS ASH2L VPS36 ZNF346 CRNKL1 TELO2
LRRC57 AASDHPPT CNPY3 GLUL CWC27 TNPO3
CHORDC1 CKAP2 CXADR ILF2 PEG10 TTI2
MANBA DCAF13 PLS1 LVRN C1QBP UBE2A
MEMO1 EIF4A3 EXTL2 MED24 GLYR1 UBXN1
MRPS18A EIF5B NIFK POLR2H HMOX2 ABCB6
NDUFB4 FNBP1L NOL10 KIF5C EXOSC9 ATP2B1
TOMM40 RBM28 GSTP1 TATDN1 FTSJ3 DAGLB
PLCG1 IFI16 HSPA4 TMEM192 MPI SMPD4
POLE4 KDM1A NUP188 TSFM DLAT FAM210A
POLR2D NOL6 PRPF40A UBAP2 MSTO1 GTF2I
SHPK NUP133 RBM12B DAB2IP SAFB LARP1
SPCS1 PDHA1 STX18 PPFIA1 NUP50 METTL13
SAAL1 QTRTD1 SUPT6H ADSL QSER1 POLR3C
TRMT1L ASUN BMP1 AFG3L2 GEMIN5 NEU1
PEX6 HDAC3 NDC80 MRRF HMGN1 TIMM44
REEP6 OTX2 LPCAT1 MTPAP SNU13 UMPS
TRIAP1 TUT1 GRSF1 NAA20 ACSS3 NCK1
ERBB2 CCDC28B XRN2 NDUFAF4 MIF PPP2R5A
SGSH CRADD MT-ND4 GATAD2A MRPL9 RAD50
OSGEPL1 ADGRL2 MTUS2 NRBF2 FAM192A DNPEP
THAP11 HEATR5B RABGEF1 POP1 HEATR3 SRRM2
CACTIN PRKD1 MRPL50 PRMT1 NIPBL STK4
SLC25A35 ECE2 RPL13A SDCBP NTMT1 TBRG4
ZFAND6 DSEL SDAD1 RPL21 PDCD5 PPIG
RALGAPB MYO5C TRMT6 RBM39 GULP1 DCP1A
IGSF1 POLG UBE3A SLC30A1 RFC4 TUBAL3
MGRN1 TPK1 KCTD10 SMAP ACIN1 UBXN7
TMEM41A DNAL1 F8A1,F8A2,F8A3 TKFC BSG ARHGEF40
FBP1 FBXL6 DFFB TRIM33 EHBP1 ATP5S
CDC20 PLEKHA7 WDR73 CD70 EMC3 SLC9A3R1
COBLL1 TRIM9 SP1 YARS2 RBM19 CKMT1A,CKMT1B
HSP90AB3P MRPL35 CCNA2 HDDC2 KDM3B PPA1
SMARCAL1 MALSU1 AURKB PPM1G EARS2 HSP90AA1
SH3GL3 MPHOSPH6 NACC2 HMGB2 GTPBP4 ABCB10
CYP2U1 BSDC1 TLK1 LEO1 MFAP1 GIT1
FLCN TYRO3 SH3PXD2A EMC4 CPS1 INTS9
IRS2 SIRT3 FUT8 CDK2 TNFAIP6 SDHAF4
KITLG ALDH3A1 GPR180 CFAP36 ANK3 CBX2
RBBP9 EML2 POLR3GL FN3K VWA5A RAVER2
(ii) Proteins enriched more than two-fold in c-MYC-WT compared with MYCL-WT (EpiP)
FIGNL2 MCEE NDUFB7 BCCIP CCDC86 HSPA4L
URB1 INTS14 MRPS10 PDHX SNCA RPL26L1
NBN DNAJC2 NDUFAF2 WDR36 UBE2G1 INTS3
NDUFB1 EIF3C WARS2 SUPV3L1 TOP2A ANKZF1
PCCA AKAP9 NOP16 EHMT2 MRPL3 KAT7
POLR3D MAPKAP1 PAIP1 GK INTS13 MT-ATP6
NF1 NABP2 OSBPL11 IMPDH2 DIEXF WDR73
BRD2 MCM7 SFXN4 HSPD1 REXO4 GEMIN4
NCAPD3 NDFIP1 BOP1 PM20D2 TRMT5 STEAP3
SSR2 MTA3 TOMM40 PDS5A SLC25A17 RIDA
GTF2A2 DCUN1D5 ORC5 CDKN2AIPNL SET TFAM
CORO7 THTPA POLR1B HSPE1 APOO NDUFS7
UBE2G2 WRAP53 HARS2 POLRMT IRF9 RBM19
PPP4R3B DPCD FBXO22 CLUH TSR1 ZNF740
ATP7A HIGD2A TIMM17A COA7 ALKBH5 TTI1
ATR ITPA PABPN1 TYMS RARS2 PHC2
MBTPS1 FAM234A LPCAT3 BMS1 INTS11 UBE2S
VAMP3 TTC12 TNPO2 NOC3L TBL3 POLR1A
PFKFB3 CARS2 FBL LSAMP ABHD11 ORC2
SH3PXD2A INCENP SMN1,SMN2 GNL3 MRPS15 MRPL17
ZNF318 ITM2C NIP7 SYF2 UCK2 MARS2
CWF19L1 INTS9 CDK1 STK26 IRF2BP2 PTCD1
RBX1 POLR3B SLC4A7 DNPH1 DIMT1 DUS3L
ULK3 IFT57 NDUFAF4 NGDN PCBP2 CEPT1
TTC33 ARMCX1 HDDC3 PPIF MDC1 PES1
CWC27 TRAP1 BRIX1 TOMM6 NCAPG PWP2
NOL11 DDX41 GCA DDX20 HEATR1 NT5DC2
KDM3B TASOR NCL MGST1 GTF2H4 SSNA1
ZC3HC1 PALD1 EEF1E1 TRMT10C NUDT3 COIL
VRK2 SYNPO2 PSMF1 PTBP3 TGS1 NOL10
DDX60 HIGD1A RAB11FIP5 C1QBP BCS1L POLD3
PHACTR4 SIK3 TRIM65 DNMT1 LYAR YY1
ASPM CABIN1 WDR43 POLD2 WDR3 DCAF1
GPD1L MAP3K4 MYC FAM162A DDX18 WDHD1
GTF3C2 MYBBP1A URB2 HMGN5 BAZ1A MDP1
STAG1 DDX21 VRK1 GUCY1B2 SLC1A3 MTMR6
COX6A1 TMEM33 UBE2D3 RFC5 RRP1 NEDD4
SAAL1 NPM3 TEX10 CDK2AP1 POLR2F RSL1D1
EDC3 PLA2G4A HMGA1 DDX24 TRRAP SELENOO
DTD2 MED23 PBX1 UTP4 H1-4 FANCI
SLC35E1 PEG10 GRPEL1 DPH2 DNAJA3 HAUS1
CCDC115 NOLC1 GNL2 POLD1 MRPS2 ZNF565
PVR AKAP1 PRRX1 NDUFAF3 PARP12 STRIP1
ZCCHC3 NELFCD PODXL2 PRR35 KDM1B BMI1
TRAPPC8 SPNS1 BLOC1S4 UMODL1 KIF21B C8orf33
NFIX AFP TTN RAVER2 NFATC2IP CHD1
UBE2D1 DHX38 CDK5RAP1 IDUA IRAK1 ORMDL3
GPAA1 B3GALT6 XPC LIN7C VWA1 MET
METTL1 COA4 CTIF SHPK PNKP
(iii) Proteins enriched more than two-fold in c-MYC-WT compared with c-MYC-ΔMB0 (EpiP)
FAM83G IFT20 DOP1B NOC3L POLR2F EXOC8
STK25 ASPM WIPI2 LSAMP KHNYN S100A3
BTAF1 GPD1L OARD1 ARF1 HACD2 VWA1
URB1 STAG2 SLC25A15 SYF2 RIDA METTL1
PCDHGA12 CCNYL1 IKBKG GXYLT1 CEP250 SMARCA4
TGFB1 NECAP1 MAP3K4 NLE1 RBM19 PRIM2
SERPINE2 PPHLN1 UTP3 PTBP3 LMF2 SHPK
SP1 STAG1 CD320 YTHDF2 ORC2 F8A1,F8A2,F8A3
GLUL SREK1 ARMC9 C7orf50 MRPL17 BMI1
PHKG2 COX6A1 RPL36A DNMT1 MARS2 C8orf33
NF1 BRI3BP LAS1L FAM162A PTCD1 CCDC93
BRD2 LPIN2 PLA2G4A HMGN5 CEPT1 MET
ATP6V0C ZNF622 PEG10 CDK2AP1 LIMD2 COA4
NCAPD3 SNX21 CCDC58 NUP50 ORC4 TTC5
SSR2 NUDT16 LYRM7 SLC16A1 LAGE3 CCDC63
PRIM1 SAAL1 WARS2 ERCC4 RMC1 PODXL2
GTF2A2 DTD2 ZNF24 UTP4 NOL10 BLOC1S4
EPHB3 WASF2 NAA16 BUD23 POLD3 CDK5RAP1
UBE2G2 CCDC115 BOP1 SELENBP1 H2AC21 SPATA5L1
PLCB3 HAPLN3 TNFRSF10B SNCA CNBP XPC
ATP7A DNAJC2 ORC5 VPS33A CAMLG MPC1
PTK2 AKAP9 HARS2 CTSC DOCK1 MIPEP
HSPA14 THTPA TIMM17A INTS13 SPR PVR
ATR CEP41 PABPN1 REXO4 CSNK2A1 AKAP1
VAMP3 XPO4 NOLC1 PDF CCDC51 SRC
PFKFB3 CSTF2T SMN1,SMN2 APOO CLPB AFP
DOCK11 QRSL1 WRNIP1 MSH3 YY1 RAVER2
ZFYVE27 TTC12 HDDC3 IGFBP5 HEATR5A CRLF3
RNASEH2B CARS2 STARD4 SMYD3 WDHD1 DDX60
SH3PXD2A C17orf75 GCA RPL10L NSD2 HIGD1A
TNS2 CRLF2 TRIM65 INTS11 MDP1 EXOG
ATG16L1 TNFRSF12A PBX1 IMP3 GLE1 POLRMT
TTI2 INCENP UQCC1 AATF MTMR6 MRPS30
ULK3 INTS9 NDUFAF1 MRPS15 THNSL1 RRP1
TTC33 MTRR EHMT2 LIG1 RBFOX2 CDC16
KDM3B TRAP1 HSPD1 POLA2 PKMYT1 KIF21B
TTC21B PTBP2 UBR5 CCDC171 MAP3K7 NFATC2IP
HEATR3 PALD1 CDKN2AIPNL TGS1 RSL1D1 TERF2
ZC3HC1 ISY1 NAF1 BAZ1A FANCI RIF1
VRK2 SYNPO2 PRORP
(iv) Commonly enriched proteins in (i) and (ii) and (iii)
KDM3B
HMGN5
URB1
PALD1
LSAMP
MET
DNAJC2
RBM19
AKAP1
INTS9
SNCA
MARS2
MAP3K4
INCENP
AKAP9
GCA
NCAPD3
FAM162A
ORC5
ULK3
POLRMT
ZC3HC1
PTCD1
NOL10
SHPK
XPC
SH3PXD2A
RAVER2
PTBP3
BOP1
PEG10
TIMM17A
SAAL1
CARS2
FANCI
HARS2
BAZ1A
PLA2G4A
APOO
WARS2
TRAP1
RSL1D1

Four groups are described: (i) proteins whose peptide counts increased more than two-fold in c-MYC-WT/HDFs compared with MYCL-WT/HDFs using SeV on day 3, 5, or 7; (ii) proteins whose peptide counts increased more than two-fold in c-MYC-WT compared with MYCL-WT using EpiP; (iii) proteins whose peptide counts increased more than two-fold in c-MYC-WT compared with c-MYC-ΔMB0 using EpiP; and (iv) commonly identified proteins. n=3 for EpiP reprogramming.

Table 3.

MS analysis of identified proteins in cells reprogrammed with MYCL-WT and c-MYC-ΔMB0 compared with MYCL-ΔMB0.

(i) Proteins enriched more than two-fold in MYCL-WT compared with MYCL-ΔMB0 (EpiP)
UBQLN2 DYNLRB1 EXOC2 KRT17 NANS ARL1
REEP5 RAB11B ARPC2 TPM1 UTP15 TMPO
SGCD WDR46 CD47 SLC44A2 RASA1 CETN2
TUBB2A ALDH6A1 STRN3 FBXW10 BAP18 SNW1
HMGB1 POTEF PDHA1 CAMK2D TM9SF3 NFS1
PPIC COMMD4 SCP2 MT-ATP6 YIPF5 MPI
HMGB3 TUSC3 COL3A1 ARF4 ATP5PB MPDU1
PCNP MYD88 GNB2 NUCKS1 LIMS1 USP15
SYAP1 RAC1 COG6 TMED2 LRBA OVCA2
CHMP4B MACF1 SOX2 PRKACA MAPK14 CALD1
UTP3 SRSF11 SSR1 MID1 DUSP12 GBP1
BLOC1S1 EXOC5 CSTF3 PCID2 THOC3 ANP32B
ST6GALNAC1 DNAJC9 CACNA2D1 TRIP12 SRSF5 USP48
MAP3K20 MICAL1 NRDC GADD45GIP1 VAC14 PDIA4
KNTC1 POLR2L MSRB3 GTF2I PDXDC1 SF3A3
BAG5 SFXN3 NOL11 ERLIN2 ZNF462 NUCB2
CD320 CRIP1 OSTC DBNL ITGB1 AGK
MRPL11 NAA10 RPL37A STT3A CTTN PPIL3
TFG ARF6 LZIC PAFAH1B1 EEF1B2 IDI1
THYN1 CCDC43 BMP1 SLC25A24 UGP2 ELN
NDRG3 NEK7 PDCL3 HOOK3 LSM2 COL4A2
TMX4 TUBB4B UGP2 LAS1L ACTB BUD31
SEPHS1 MYO1E TNS3 HLA-H RABL3 MAP2
RPL36A FNTA VPS26B DCN RWDD1 PAIP1
MYDGF SRBD1 EHD1 PUM1 TOMM20 ITGA5
OPTN DBI ANKFY1 PUS7 CRABP2 GPX8
GNAQ SUGP2 KBTBD3 KPNA4 VDAC3 TXLNG
ACSL4 MTA1 SCPEP1 METTL26 EDIL3 ATP5MG
ATP5ME MAP7D1 FBLN2 B4GALT4 PLA2G4A PIK3R4
ABI3BP ACTG1 LDLR MBD5 CTNNA1 PLBD2
ASAH1 HINT1 EXOSC7 CSRP1 RPL23A ZYX
GNS HMGN1 DIP2B GNB1 TMEM165 COX7C
WDR61 PTGR1 PITRM1 SNRPB2 DNAH6 H3-3A,H3-3B
ARL8A TMSB4X METTL14 CNN2 DPP9 NCKAP1
MAP3K20 FAM114A1 TMSB10 PPIB ENDOD1 AHNAK
NDRG1 FTH1 CNPY3 S100A10 NDUFB11 PGM2
PITPNA SGTA HABP2 C1orf198 NAA50 PODXL
NIF3L1 SGPL1 SRP9 MARCKSL1 DNAJC8 CFL2
NME2 CD59 NDUFB9 TOR1AIP1 NXN STAT6
PFDN1 DHRS4 RBPJ NDUFA4 MRPS17 TP53BP1
ATG3 GSPT1 DCTN5 ACSS2 REXO2 ATAD1
ACIN1 BLOC1S3 TMED1 GSTK1 PEBP1 EIF3K
RAB14 RFC3 AKR1B1 ISLR S100A13 GPX7
SNAP23 CD55 TALDO1 NOP14 SLC25A6 TRIO
EMC2 RPS15A DSTN POLR2A OSBPL3 TSPYL5
(ii) Proteins enriched more than wo-fold in c-MYC-ΔMB0 compared with MYCL-ΔMB0 (EpiP)
UBQLN2 ACIN1 NEK7 PITRM1 PDLIM5 CAMK2D
HMGB1 SRSF11 RAB11B ITGA1 H3-3A,H3-3B CRABP2
REEP5 OPTN ANKFY1 ISLR C1orf198 NCKAP1
NDRG1 KNTC1 CD47 SRSF5 LUZP1 HMGN1
SGCD PAIP1 PRKACA ERLIN2 IDI1 MAP2
MAP3K20 NIF3L1 SCRN3 MRPS17 HABP2 TOR1AIP1
TUBB2A POTEF FAM114A1 TOMM20 PAFAH1B1 ARL1
CCDC43 COG6 NOLC1 UGP2 ITGA5 OSBPL3
PCNP TSPYL5 COMMD4 LSM2 CHIC1 ANP32B
TMX4 DYNLRB1 EHD1 UTP15 SMTN STT3A
BLOC1S1 STRN3 PPP4C PUM1 DUSP12 VPS26B
SYAP1 ASAH1 FNTA MYO1E MEAF6 APP
PPIC ATP5ME GNAQ TP53RK NMT1 GALNT1
NME2 OVCA2 SEMA7A POLR2L NDUFA4 SSR1
ACSL4 RAC1 RPL36A MYO6 LIMS1 YIF1A
HMGB3 OSTC FTH1 PUS7 CLASP2 UGP2
FBXW10 DBI PTGR1 PIK3R4 ILF3 USP48
MAP3K20 PDHA1 KRT17 MYD88 RASA1 PPIB
NDRG3 SFXN3 ARPC2 REXO2 GALE METTL26
GNS TNS3 ABI1 DBNL TXLNG MYO1D
UTP3 DHRS4 PAIP1 USP15 PPIL3 NDUFS6
SEPHS1 MPDU1 PCID2 SRBD1 RFC3 PPIF
BAG5 DNAJC9 SEC24A ACTG1 SCLY SMARCC2
ATG3 MAPK14 UBQLN1 LZIC MPV17 STAM2
SCPEP1 MRPS24 MTA1 TRIP12 VAC14 BMP1
TFG PLA2G4A BAP18 THOC3 DCTN5 PGM2
MT-ATP6 NOL11 METTL14 SCP2 COG7 CERS2
MRPL11 SUGP2 EXOC5 POLR2A MCRIP1 SLIT3
CHMP4B TUSC3 BLOC1S3 CSTF3 CTNNA1 HOOK3
SGPL1 DIP2B DUSP23 GNB2 SENP3 COL3A1
MICAL1 PFDN1 SOX2 GSPT1 EIF2B1 ITGB1
DCN NRDC LDLR GADD45GIP1 SETD7 AGK
CUL4A SGTA CNPY3 KPNA4 DNASE2 MPHOSPH10
ARF6 PODXL MPI FADS2 RAI14 BOLA2,BOLA2B
HLA-H ARL8A HINT1 NSA2 TPMT IMPACT
MACF1 PDXDC1 GSTK1 ATAD1 EDIL3 USP9X
THYN1 CD320 CD59 METAP1 IGF2R OCIAD2
MYDGF PITPNA FBLN2 TPM1 NAA50 CACNA2D1
NACA4P MAP7D1 NANS MBD5 EEF1B2 YIPF5
NAA10 WDR46 TM9SF3 DCTD EEA1 TMSB10
NDUFB9 LRRC17 YAP1 GTF2I CD55 SNAP23
ABI3BP WDR61 RABL3 PRKRA DNAJC8 EIF3H
SNW1 LMCD1 KLF4 PSMD4 S100A10 KBTBD3
SNRPB2 COL4A2 CFL2 LSM5 FBXO22 ACYP1
ARF4 VDAC3 ALDH6A1 CYP51A1 CBX3 SNX27
ATP5MG CNN1 CLINT1 ACSS2 EIF2B3 SLC25A24
CTTN CALD1 DYNC1LI1 NDUFAF2 S100A13 CDC42BPB
TMPO EWSR1 ANTXR2 TP53BP1 RBM17 IDH3G
RPL37A SPATS2L PHLDB1 CARHSP1 CFAP74 EMC2
PLS1 HSD17B7 FAP NXN TUBB4B SF3A3
MTR OSTF1 TMSB4X SRP9 VASP EXOC2
NCBP1 SFXN4 NUCKS1 RPS29 MANF COPS6
VPS4B AHNAK CSRP1 SLC25A6 CARM1 FKBP2
TMOD3 RBPJ TALDO1 ATP5PB PRPF4B TBC1D15
GPX7 B4GALT4 MSRB3 DNAH6 COX7C OGFR
ALDH1L2 CRIP1 AP3M1 SCAMP2 C1orf50 ELN
TSN TOR1B PDS5A PDIA4 RWDD1 GABPA
DYNLL1 USP47 ENDOD1 NUCB2 GINS4 DR1
FKBP5 OAS2 MRTO4 NFS1 NPC2 ABI2
SERPINE2 NDUFAF4 ZYX HACD3 EXOSC7
(iii) Commonly enriched proteins in (i) and (ii)
WDR46 TUSC3 RBPJ NFS1 NIF3L1 DNAJC8
MYO1E MYD88 FBXW10 ARF4 TM9SF3 TMPO
RAC1 SFXN3 CAMK2D MPDU1 CTNNA1 EEF1B2
TMSB10 MACF1 NUCKS1 OVCA2 CHMP4B COL3A1
LDLR DBNL PRKACA ANP32B PCNP S100A10
CRABP2 EXOC5 TRIP12 SLC25A24 PAIP1 NEK7
NOL11 DNAJC9 GADD45GIP1 SF3A3 ARL1 MICAL1
POLR2L CRIP1 GTF2I AGK PODXL S100A13
TOMM20 CCDC43 AHNAK PPIL3 REXO2 STT3A
CFL2 SRBD1 ENDOD1 IDI1 FNTA H3-3A,H3-3B
POTEF SUGP2 PDHA1 ELN FBLN2 SCPEP1
TSPYL5 MTA1 HOOK3 COL4A2 NDRG3 TXLNG
SGTA TMSB4X HLA-H MAP2 EXOC2 MPI
REEP5 ACTG1 PUM1 ATP5MG SOX2 HMGN1
SGCD HINT1 KPNA4 PIK3R4 DBI UBQLN2
HMGB3 PTGR1 METTL26 COX7C TUBB2A NDUFB9
SYAP1 EMC2 B4GALT4 NCKAP1 SRP9 PDXDC1
UTP3 RPL36A MBD5 ASAH1 FAM114A1 TOR1AIP1
BLOC1S1 CD59 SNRPB2 PGM2 CD55 MAP7D1
MAP3K20 NUCB2 C1orf198 TP53BP1 SNAP23 COG6
KNTC1 BLOC1S3 ACSS2 ATAD1 UGP2 TNS3
BAG5 STRN3 GSTK1 RPL37A KRT17 SGPL1
CD320 SCP2 NANS RFC3 DCTN5 CSRP1
TFG GNB2 UTP15 TALDO1 USP48 ATG3
THYN1 SSR1 BAP18 ISLR NDUFA4 EDIL3
TMX4 CSTF3 YIPF5 POLR2A ITGB1 ZYX
ARL8A CACNA2D1 LIMS1 OSBPL3 ATP5PB PCID2
GNAQ NRDC THOC3 GPX7 PUS7 RASA1
ACSL4 MSRB3 SRSF5 PPIC SRSF11 DNAH6
ATP5ME OSTC VAC14 MYDGF USP15 ALDH6A1
ABI3BP LZIC ARF6 HMGB1 MT-ATP6 COMMD4
GNS BMP1 UGP2 ERLIN2 NAA10 CNPY3
MAP3K20 VPS26B LSM2 FTH1 ITGA5 HABP2
NDRG1 ANKFY1 RABL3 DUSP12 CD47 DHRS4
NME2 KBTBD3 RWDD1 CTTN MRPL11 SNW1
PFDN1 EHD1 PLA2G4A PPIB OPTN ARPC2
MAPK14 EXOSC7 SLC25A6 SEPHS1 WDR61 TPM1
ACIN1 DIP2B NAA50 DCN PDIA4 GSPT1
DYNLRB1 PITRM1 NXN PAFAH1B1 VDAC3 TUBB4B
RAB11B METTL14 MRPS17 PITPNA CALD1

Three groups are described: (i) proteins whose peptide counts increased more than two-fold in MYCL-WT compared to MYCL-ΔMB0; (ii) proteins whose peptide counts increased more than two-fold in c-MYC-ΔMB0 compared to MYCL-ΔMB0; and (iii) commonly identified proteins. n = 3.

We also compared phosphorylated proteins during SeV reprogramming with MYCL and c-MYC. In total, there was more than a two-fold relative increase of 17 phosphorylated proteins with MYCL-WT and 132 phosphorylated proteins with c-MYC-WT. The GO analysis indicated that the phosphorylated proteins increased by MYCL included cytoskeleton-related proteins and those increased by c-MYC included transcription-related proteins (Supplementary Fig. S11).

MYCL regulates RNA processing-related proteins during reprogramming via the MB2 domain

Our analysis also revealed that, along with the MYCL MB0 domain, the MYCL MB2 domain is important for reprogramming (Fig. 2B). It has been reported that the c-MYC MB2 domain is involved in transformation activity, and tryptophan 135 within the MB2 domain is necessary for this activity10. MYCL also has a tryptophan residue within its MB2 domain but little transformation activity23. We hypothesized that this domain in MYCL has reprogramming function. We therefore produced a mutant in which tryptophan 96 was substituted with glutamate (W96E). This tryptophan is equivalent to tryptophan 135 in c-MYC (Fig. 4A and Supplementary Fig. S5B). We confirmed the expression of MYCL-W96E by western blotting (Supplementary Fig. S12). Next, we examined the effect of MYCL-W96E for reprogramming. HDFs were transfected with reprogramming factors including MYCL-WT or -W96E. MYCL-W96E could not induce iPSC-like colonies, suggesting tryptophan 96 is crucial for reprogramming (Fig. 4B, C). We thus hypothesized that the residue might be important for MYCL to bind to other proteins. To identify the binding proteins, we produced GST-fusion recombinant proteins of the MYCL MB2 domain (Fig. 4A). GST-MYCL-MB2-WT or -W96E proteins were immobilized on glutathione Sepharose, and affinity columns were prepared. Cell lysates were applied to the column, and, after washing, the bound proteins were eluted. We used the cell lysates from reprogramming HDFs, but since it was difficult to collect a large amount, we also used cell lysates from hiPSCs. The reason for using the hiPSC lysates is that many of the proteins expressed in reprogramming HDFs are highly expressed in hiPSCs as well16,2427.

Figure 4.

Figure 4

MYCL regulates RNA processing-related proteins during reprogramming via the MB2 domain. (A) W96 and W135 in the MB2 domain of MYCL and c-MYC, respectively. The structure with the recombinant protein of the MB2 domain of MYCL-WT/W96E is shown below. The numbers on the right indicate amino acid lengths. (B) The number of iPSC-like and non-iPSC-like colonies derived from 1 × 105 HDFs transduced with EpiP including MYCL-WT or MYCL-W96E on day 21. Mean ± SD values are shown. n = 3, *p < 0.05 by unpaired t-test. (C) Representative images of reprogramming HDFs 21 days after the transduction of EpiP, including MYCL-WT or MYCL-W96E. Scale bars, 100 μm. (D) Venn diagram of enriched proteins between reprogramming HDFs and hiPSCs by AP-MS. A list of the 25 commonly enriched proteins is shown below. Blue indicates RBP (23 in total). (E) Molecular function from the GO analysis of the 25 commonly identified proteins in (D).

We identified 31 candidate proteins that bind to the MB2 domain of MYCL-WT but not of MYCL-W96E during reprogramming in the HDF lysates (Fig. 4D and Table 4). Of those 31 proteins, 25 proteins were also identified using hiPSC lysates, and 23 were RNA-binding proteins (RBPs; Fig. 4D, genes written in blue). Six proteins were identified only in the reprogramming HDFs lysates: HNRNPK, DDX17, C1QBP, KBTBD3, COPG2, and SIKE1, of which HNRNPK, DDX17, and C1QBP are RBPs. From these results, there were 26 RBPs identified in the HDF lysates in total. We confirmed the function of the 31 proteins using a public database (https://www.nextprot.org/)28 and found 16 of them are involved in RNA processing. A GO analysis using DAVID also showed that the 31 proteins are related to controlling pre-mRNA splicing, capping, and polyadenylation, suggesting functions in mRNA export, turnover, localization, and translation (Fig. 4E). These results suggested that MYCL interacts with RBPs via its MB2 domain and promotes reprogramming by post-transcriptional regulation.

Table 4.

AP-MS analysis of identified proteins in MYCL-MB2-WT using cell lysates from reprogrammed HDFs and hiPSCs.

(i) Proteins enriched more than two-fold in MYCL-MB2-WT compared with MYCL-MB2-W96E (reprogramming HDFs) (31)
HNRNPA1 HNRNPD HNRNPDL HNRNPA2B1 HNRNPA0 HNRNPA3
KHDRBS1 HNRNPAB ALYREF DDX5 HNRNPU SYNCRIP
HNRNPR HNRNPK DDX17 C1QBP FAU RPL22
RPL37A RPL23A NCL RPS24 RPL31 RPS4X
RPS7 CIRBP MCFD2 KBTBD3 COPG2 PTGES3
SIKE1
Italic value RNA binding proteins
Bold italic value : RNA processing proteins
(ii) Proteins enriched more than two-fold in MYCL-MB2-WT compared with MYCL-MB2-W96E (hiPSCs) (60)
HNRNPA1 HNRNPD HNRNPDL HNRNPA2B1 HNRNPA0 HNRNPA3
KHDRBS1 HNRNPAB ALYREF DDX5 HNRNPU SYNCRIP
HNRNPR HNRNPK PRPF31 DDX42 LYAR YBX1
FAU RPL22 RPL37A RPL23A NCL RPS24
RPL31 RPS4X RPS7 CIRBP RPL23 RPL30
LSM14A DDX18 NSUN2 ILF3 TRMT1 SRP9
IGF2BP1 SRP14 ANP32A ILF2 HACD3 UBE2N
GPC4 MDK BAX ANP32E ANP32B APEX1
PTGES3 MCFD2 CFDP1 ACTR2 ITGB1 SFRP1
DSTN PDHB HADHA HADHB NDUFS5 CNBP
Italic value RNA binding proteins
Bold italic value : RNA processing proteins
(iii) Common enriched proteins enriched between reprogramming HDFs and hiPSCs (25)
HNRNPA1 HNRNPD HNRNPDL HNRNPA2B1 HNRNPA0 HNRNPA3
KHDRBS1 HNRNPAB ALYREF DDX5 HNRNPU SYNCRIP
HNRNPR FAU RPL37A RPL22 RPL23A CIRBP
RPS24 RPS7 RPS4X RPL31 NCL PTGES3
MCFD2
Italic value RNA binding proteins
Bold italic value : RNA processing proteins

Three groups are described: (i) protein interactors whose peptide counts increased in reprogramming HDFs more than two-fold in MYCL-MB2-WT than MYCL-MB2-W96E; (ii) protein interactors whose peptide counts increased in hiPSCs more than two-fold in MYCL-MB2-WT compared to MYCL-MB2-W96E; and (iii) commonly identified proteins. n = 1.

Discussion

Here we described the molecular function of MYCL during reprogramming and compared it to the c-MYC function by focusing on MYC Box domains. We found that the MB0 and MB2 domains are important for reprogramming, and deleting either region compromised the reprogramming ability of MYCL. Proteomic analysis revealed that MYCL regulates the expression of cell adhesion-related proteins during reprogramming via the MB0 domain (Fig. 3C, D). We also found the possibility that the same domain is regulated by post-translational modifications (PTM), as discussed below. It is known that cell-substrate adhesion is closely related to the mesenchymal-epithelial transition (MET)29 and that MET occurs during the reprogramming process3032. We speculate that MYCL promotes iPSC-like colony formation via the MET process by upregulating cell adhesion-related genes. Furthermore, we identified that the MB2 domain is required for MYCL to promote reprogramming by binding to RBPs, especially RNA processing-related proteins (Fig. 4D, E). It has been reported that RBPs regulate MET through post-transcriptional regulation. For example, heterogeneous nuclear ribonucleoprotein (hnRNP) A1 regulates the alternative splicing of Rac1 to control MET33. These findings suggest that MYCL regulates the RNA processing of cell adhesion-related genes transcribed by MYCL itself or other genes. Therefore, we hypothesize that transcriptional and post-transcriptional regulation by MYCL promotes MET, which increases the efficiency of reprogramming and leads to higher quality iPSCs.

Western blotting revealed that MYCL protein has a unique expression pattern (Supplementary Fig. S8 and S12). The calculated molecular weight of MYCL is about 40 kDa (364 aa), but we detected three strong bands at around 60 kDa, which we verified with second antibody (Supplementary Fig. S13). Since the expression of MYCL-ΔMB0 showed a strong single band, we speculate that the MYCL MB0 domain is the PTM site (Supplementary Fig. S8). Such a phenomenon was not observed in c-MYC (Supplementary Fig. S7). One possible type of relevant PTM is phosphorylation. Phosphorylation is crucial for protein function. For example, RNA polymerase II (Pol II) is required for transcription pauses in a promoter-proximal position during transcription initiation. In order to initiate transcription, the C-terminal domain of Pol II must be phosphorylated by P-TEFb34. In addition, the phosphorylation of c-MYC on threonine 58 in the MB1 domain promotes c-MYC binding to F-box and WD repeat domain containing 7 (FBXW7), causing the ubiquitination of c-MYC, which triggers c-MYC degradation35. Similarly, MYCL might undergo phosphorylation to change its activity and interaction with binding proteins. However, this hypothesis requires further study.

Comprehensive proteomic analysis suggested that the MYCL MB0 domain influences the expression of cell adhesion-related proteins, and MYCL shows an up-regulation of phosphorylated cytoskeletal proteins (Fig. 3C, D, and Supplementary Fig. S11A). Cell adhesion is mediated by adhesion molecules, such as integrins and cadherins, which function in the extracellular matrix (ECM) and cell–cell adhesion and are important for cell communication and the regulation of fundamental physiological processes such as tissue development and maintenance36,37. Human iPSCs and hESCs have unique focal adhesion localization, and appropriate adhesion to the ECM is required to regulate reprogramming via MET and maintain pluripotency3840. Accordingly, our study supports MYCL regulating cell-substrate adhesion through its MB0 domain to promote reprogramming. In other words, MYCL might regulate proteins involved in cell adhesion and the cytoskeleton directly or indirectly to cause MET and promote reprogramming. In c-MYC, loss of the MB0 domain positively affects iPSC-like colony formation, suggesting that this domain has a different function compared to MYCL. This functional difference is somewhat surprising since the domain is well conserved (Supplementary Fig. S5B). We would like to clarify this point in the future.

We also found that the MB2 domain has an important function in MYCL-reprogramming (Fig. 2B,C). Deleting the MB2 domain completely compromised the reprogramming ability of MYCL. In c-MYC, the MB2 domain has an important function in transformation activity14, and tryptophan 135 in the MB2 domain is essential for this activity. The equivalent tryptophan residue in MYCL is tryptophan 96. MYCL has little transformation activity, but we showed that the mutation of tryptophan 96 completely lost the reprogramming ability of MYCL. To further investigate the function, we sought interacting proteins by affinity column chromatography. We found 31 proteins, including 26 RBPs, that interact with the MYCL MB2 domain (Table 4, genes written in blue). A GO analysis suggested that some of the 31 proteins are involved in RNA processing (Table 4). It has been reported that altered RNA processing affects somatic cell reprogramming41. Therefore, we hypothesize that MYCL also promotes MET in reprogramming by regulating RNA processing via interactions with RBPs at its MB2 domain. An illustrative summary of how MYCL regulates cell reprogramming through these two domains is shown in Fig. 5.

Figure 5.

Figure 5

Model of the reprogramming process by MYCL. MYCL promotes iPSC-like colonies via its MB0 and MB2 domains. The MB0 domain regulates the expression of cell-adhesion proteins, possibly via post-translational modifications (PTM). The MB2 domain regulates RNA processing by interacting with RNA-binding proteins (RBP). We speculate that MYCL promotes reprogramming through the synergistic effects of these two mechanisms.

To conclude, we have demonstrated that MYCL promotes more efficient reprogramming than c-MYC, regulates the expression of cell adhesion and cytoskeletal proteins, and is involved in RNA processing via a single tryptophan residue in the MB2 domain. Following these findings, we propose that MYCL causes MET by regulating the expression of proteins involved in the promotion of reprogramming from the RNA-processing stage. Further elucidation of the function of MYCL in reprogramming will improve the quality and efficiency of iPSC generation.

Material and methods

Cell culture

HDFs (106-05f.) were purchased from Cell Applications, Inc. HDFs were cultured in DMEM (08459-64, Nacalai Tesque) supplemented with 10% FBS (10439-024, gibco) and 1% penicillin and streptomycin (15140-122, Pen/Strep, gibco). The hiPSC clone 201B7 was used in this study2. iPSCs were cultivated on iMatrix-511 (NP892-012, Nippi)-coated (0.5 μg/cm2) cell culture plates with StemFit (AK03N, Ajinomoto) supplemented with bFGF and passaged via dissociation into single cells using TrypLE Select (A12859-01, Life Technologies) on day 7 following a previously reported protocol42.

Generation of iPSCs

A frozen stock of HDFs was thawed and cultured for four days, and then 1 × 105 cells were collected by trypsinization. With SeV, HDFs were transduced with the CytoTune-iPS 2.0 (c-MYC) or CytoTune-iPS 2.0L (MYCL) Sendai Reprogramming Kit (DV-0304, DV-0305, ID Pharma). With EpiP, HDFs were electroporated with 1.2 μg of plasmid mixtures with the Neon Transfection System (MPK1096 and MPK10096, Invitrogen). The plasmid mixtures included pCXLE-SOX2, -KLF4, -OCT3/4-shp53, -LIN28A, and pCXWB-EBNA1 with wild-type or mutant pCXLE-c-MYC or -MYCL17. The mixing ratio of SOX2, KLF4, OCT3/4-shp53, LIN28A, EBNA1, and c-MYC/MYCL was 1:1:2:1:0.5:2. After that, the cells were plated in a 6-well plate and cultured in StemFit AK03N without bFGF with iMatrix-511 at 0.25 μg/cm2 in SeV or 0.125 μg/cm2 in EpiP. The culture medium was changed the next day and every three days after that. The colonies were counted 21 days after plating.

Episomal plasmid vector construction for deletion mutants of c-MYC and MYCL

We previously generated pCXLE-c-MYC and -MYCL from human cDNAs encoding c-MYC and MYCL amplified by PCR and cloned into pENTR1A17. Primers for the deletion mutants were designed using the Primer Design tool for the In-Fusion HD Cloning Kit (639650, Takara) and inserted into pENTR1A. The switch from pENTR1A to pCXLE was done using the Gateway system (11791020, Invitrogen). The primers used are listed in Table S1.

Immunostaining

The cells were fixed with 4% formaldehyde (163-20145, Wako) for 20 min at room temperature. Then, the fixed cells were treated with PBS (14249-24, Nacalai Tesque) containing 0.5% Triton X-100 (35501-15, Nacalai Tesque) and 3% bovine serum albumin (01281-84, BSA, Nacalai Tesque) for 20 min at room temperature for permeabilization. The cells were incubated with primary antibodies diluted in PBS containing 3% BSA at 4℃ overnight. After washing with PBS, the cells were incubated with fluorescence-conjugated secondary antibodies for 1 h at room temperature. Nuclei were visualized with Hoechst 33342 (346-07951, DOJINDO). Anti-TRA-1-60 (1:500, 560071, BD Pharmingen, and 1:500, 09-0068, Stemgent) and Alexa 488-conjugated goat anti-mouse IgG, IgM (H + L) (1:250, A10680, Invitrogen) were used as the antibodies.

Imaging and quantification

Stained cells were imaged using a BZ-9000 imaging system (KEYENCE) or ArrayScan High-Content Systems (Thermo Fisher Scientific). HCS Studio 2.0 Cell Analysis Software (Thermo Fisher Scientific) was used to quantify cell counts and signal intensities. The Cellomics BioApplication system (Thermo Fisher Scientific) was programmed to capture and analyze 25 images per well. The total cell number was detected by Hoechst 33342 staining. The number of TRA-1-60 ( +) cells was calculated as the number of TRA-1-60 ( +) cells among Hoechst ( +) cells. TRA-1-60 ( +) cells were calculated by dividing this number by the total cell number.

Flow cytometry

Transduced cells were harvested with 0.25% trypsin/1 mM EDTA (25200-056, gibco) each day after the transduction for the analysis. At least 5 × 104 cells were stained with the following antibodies in FACS buffer (2% FBS, 0.36% glucose (16806-25, Nacalai Tesque), 50 μg/μL Pen/Strep in PBS) for 30 min at room temperature: BV510-conjugated anti-TRA-1-60 (1:40, 563188, BD Biosciences) and PE-Cy7-conjugated anti-CD13 (1:40, 561599, BD Biosciences) antibodies. The analysis was performed using MACSQuant Analyzers (Miltenyi Biotec). Negative controls used a mixture of HDFs without any EpiP transduction and reprogramming HDFs electroporated with EpiP including c-MYC or MYCL. “Isotype” means mixed HDFs stained with the isotype control of anti-TRA-1-60 (1:40, 563082, BD Biosciences) and -CD13 (1:40, 557646, BD Biosciences) antibodies.

SDS-PAGE

Cells were lysed with SDS sample buffer (0.125 M Tris-base (35434-21, Nacalai Tesque), 0.96 M glycine (17109-35, Nacalai Tesque), and 17.3 mM SDS (31606-75, Nacalai Tesque)) containing 3-mercaptoethanol (139-16452, Wako). Samples were applied and separated in an 8% polyacrylamide gel composed of 30% (w/v)-Acrylamide/Bis Mixed Solution (29:1) (06141-35, Nacalai Tesque), Separating Gel Buffer Solution (4x) (30651-05, Nacalai Tesque) and Stacking Gel Buffer Solution (4x) (32158-25, Nacalai Tesque) for SDS-PAGE.

Western blotting

Proteins on an SDS-PAGE gel were transferred to a PVDF membrane (IPVH00010, Immobilon-P, Millipore) and probed with the following antibodies using an iBind Flex system (SLF2000, SLF2010 and SLF2020, Invitrogen): anti-human MYCL (1:250, AF4050, R&D) (1:250, C-20, sc-790, Santa Cruz), anti-human c-MYC (1:500, 9E10, sc-40, Santa Cruz, and 1:500, D84C12, CST), anti-β-actin (1:1000, A5441, SIGMA), anti-Goat (1:3000, ab6741-1, abcam), anti-mouse (1:3000, 7076S, CST), and anti-rabbit (1:3000, 7074S, CST) antibodies.

Preparation of recombinant proteins and affinity purification (AP)

The MB2 region of MYCL-WT or -W96E was cloned into pGEX-6P-1. The plasmids were transformed into BL21 E. coli (DE3) (L1198, Promega) competent cells. The fusion proteins, GST-MYCL-WT-MB2 and GST-MYCL-W96E-MB2, were induced by treatment with 0.5 mM IPTG (19742-94, Nacalai Tesque) for 4 h at 37 °C. The proteins were purified using glutathione Sepharose beads (17-0756-01, GE Healthcare). Human iPSCs or reprogramming HDFs were lysed in RIPA buffer (20 mM Tris/HCl (pH 7.6) (35436-01, Nacalai Tesque), 1% NP-40 (25223-75, Nacalai Tesque), 0.1% SDS, 150 mM NaCl (31320-05, Nacalai Tesque), and protease inhibitor (25955-11, Nacalai Tesque)) and then centrifuged. Cell lysates (supernatant) were transferred into a column (29922, Thermo Fisher Scientific) packed with beads conjugated with GST- MYCL-WT or -W96E proteins. After washing, binding proteins were eluted in lysis buffer (12 mM sodium deoxycholate (190-08313, Wako), 12 mM sodium lauroyl sarcosinate (192-10382, Wako), and 100 mM Tris-HCl (pH9.0) (314-90381, NIPPON GENE)) for the MS analysis. The iPSC lysates were prepared 6 days after passaging in two 10-cm dishes (n = 1), and reprogramming HDF lysates were prepared 3 days after SeV transduction in five 10-cm dishes (n = 1).

GO analysis by DAVID

The Database for Annotation, Visualization, and Integrated Discovery (DAVID Bioinformatics Resources 6.8) was used to identify enriched biological GO terms and KEGG pathway4345. For more information, please visit the DAVID website (https://david.ncifcrf.gov/home.jsp) and KEGG Database website (https://www.kegg.jp/kegg/kegg1.html).

The methods for MS are described in the Supplementary methods.

Supplementary Information

Acknowledgements

This research was supported by AMED under Grant Number JP21bm0104001 and a grant from the Fujiwara Memorial Incorporated Foundation. We thank Dr. C. Okubo, Dr. H. Kagawa, Dr. T. Yamakawa, Dr. K. Okita, and Dr. K. Takahashi for scientific discussions; Dr. A. Ohta and Dr. Y. Nishi for technical assistance with the ArrayScan analysis; and Dr. P. Karagiannis for reading the manuscript.

Author contributions

C.A. and M.N. wrote the main manuscript text. C.A. mainly prepared all figures (supported by C.S., Y.C., T.I., and M.N.). Proteome analysis was done by Y.K. and M.I.. All authors reviewed the manuscript.

Competing interests

M.I. is a scientific adviser (without salary) of xFOREST therapeutics. Other authors do not provide a competing interest statement.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-03260-5.

References

  • 1.Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024. [DOI] [PubMed] [Google Scholar]
  • 2.Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]
  • 3.Azuma K, Yamanaka S. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Regen. Ther. 2016;4:36–47. doi: 10.1016/j.reth.2016.01.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Huang C-Y, et al. Human iPSC banking: barriers and opportunities. J. Biomed. Sci. 2019;26:87. doi: 10.1186/s12929-019-0578-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Moradi S, et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res. Ther. 2019;10:341. doi: 10.1186/s13287-019-1455-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Koyanagi-Aoi M, et al. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proc. Natl. Acad. Sci. 2013;110:20569–20574. doi: 10.1073/pnas.1319061110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc. Natl. Acad. Sci. 2010;107:14152–14157. doi: 10.1073/pnas.1009374107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Baluapuri A, Wolf E, Eilers M. Target gene-independent functions of MYC oncoproteins. Nat. Rev. Mol. Cell Biol. 2020;21:255–267. doi: 10.1038/s41580-020-0215-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Varmus HE. The molecular genetics of cellular oncogenes. Annu. Rev. Genet. 1984;18:553–612. doi: 10.1146/annurev.ge.18.120184.003005. [DOI] [PubMed] [Google Scholar]
  • 10.Oster SK, Mao DYL, Kennedy J, Penn LZ. Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene. 2003;22:1998–2010. doi: 10.1038/sj.onc.1206228. [DOI] [PubMed] [Google Scholar]
  • 11.Beaulieu M-E, Castillo F, Soucek L. Structural and biophysical insights into the function of the intrinsically disordered myc oncoprotein. Cells. 2020;9:1038. doi: 10.3390/cells9041038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Amati B, et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992;359:423–426. doi: 10.1038/359423a0. [DOI] [PubMed] [Google Scholar]
  • 13.Zhang Q, et al. MB0 and MBI are independent and distinct transactivation domains in MYC that are essential for transformation. Genes. 2017;8:134. doi: 10.3390/genes8050134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kalkat M, et al. MYC protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis. Mol. Cell. 2018;72:836–848.e7. doi: 10.1016/j.molcel.2018.09.031. [DOI] [PubMed] [Google Scholar]
  • 15.Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B. 2009;85:348–362. doi: 10.2183/pjab.85.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tanabe K, Nakamura M, Narita M, Takahashi K, Yamanaka S. Maturation, not initiation, is the major roadblock during reprogramming toward pluripotency from human fibroblasts. Proc. Natl. Acad. Sci. 2013;110:12172–12179. doi: 10.1073/pnas.1310291110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Okita K, et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods. 2011;8:409–412. doi: 10.1038/nmeth.1591. [DOI] [PubMed] [Google Scholar]
  • 18.Xing, Q. R. et al. Diversification of reprogramming trajectories revealed by parallel single-cell transcriptome and chromatin accessibility sequencing. Sci. Adv.6, eaba1190 (2020) [DOI] [PMC free article] [PubMed]
  • 19.Wolf E, Eilers M. Targeting MYC proteins for tumor therapy. Annu. Rev. Cancer Biol. 2020;4:61–75. [Google Scholar]
  • 20.Schwanhäusser B, et al. Global quantification of mammalian gene expression control. Nature. 2011;473:337–342. doi: 10.1038/nature10098. [DOI] [PubMed] [Google Scholar]
  • 21.Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
  • 22.Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucl. Acids Res. 2009;37:1–13. doi: 10.1093/nar/gkn923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wasylishen AR, et al. New model systems provide insights into Myc-induced transformation. Oncogene. 2011;30:3727–3734. doi: 10.1038/onc.2011.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–317. doi: 10.1038/nature05934. [DOI] [PubMed] [Google Scholar]
  • 25.Yu J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920. doi: 10.1126/science.1151526. [DOI] [PubMed] [Google Scholar]
  • 26.Sone M, et al. Hybrid cellular metabolism coordinated by Zic3 and Esrrb synergistically enhances induction of naive pluripotency. Cell Metab. 2017;25:1103–1117.e6. doi: 10.1016/j.cmet.2017.04.017. [DOI] [PubMed] [Google Scholar]
  • 27.Maekawa M, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature. 2011;474:225–229. doi: 10.1038/nature10106. [DOI] [PubMed] [Google Scholar]
  • 28.Zahn-Zabal M, et al. The neXtProt knowledgebase in 2020: data, tools and usability improvements. Nucl. Acids Res. 2020;48:D328–D334. doi: 10.1093/nar/gkz995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rodriguez-Boulan E, Macara IG. Organization and execution of the epithelial polarity programme. Nat. Rev. Mol. Cell Biol. 2014;15:225–242. doi: 10.1038/nrm3775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Li R, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010;7:51–63. doi: 10.1016/j.stem.2010.04.014. [DOI] [PubMed] [Google Scholar]
  • 31.Sakurai K, et al. Kinome-wide functional analysis highlights the role of cytoskeletal remodeling in somatic cell reprogramming. Cell Stem Cell. 2014;14:523–534. doi: 10.1016/j.stem.2014.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Pei D, Shu X, Gassama-Diagne A, Thiery JP. Mesenchymal–epithelial transition in development and reprogramming. Nat. Cell Biol. 2019;21:44–53. doi: 10.1038/s41556-018-0195-z. [DOI] [PubMed] [Google Scholar]
  • 33.Bonomi S, et al. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucl. Acids Res. 2013;41:8665–8679. doi: 10.1093/nar/gkt579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Price DH. Regulation of RNA polymerase II elongation by c-Myc. Cell. 2010;141:399–400. doi: 10.1016/j.cell.2010.04.016. [DOI] [PubMed] [Google Scholar]
  • 35.Welcker M, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. 2004;101:9085–9090. doi: 10.1073/pnas.0402770101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Tamkun JW, et al. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell. 1986;46:271–282. doi: 10.1016/0092-8674(86)90744-0. [DOI] [PubMed] [Google Scholar]
  • 37.Hynes R. Integrins: A family of cell surface receptors. Cell. 1987;48:549–554. doi: 10.1016/0092-8674(87)90233-9. [DOI] [PubMed] [Google Scholar]
  • 38.Närvä E, et al. A strong contractile actin fence and large adhesions direct human pluripotent colony morphology and adhesion. Stem Cell Rep. 2017;9:67–76. doi: 10.1016/j.stemcr.2017.05.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Santoro R, Perrucci GL, Gowran A, Pompilio G. Unchain My heart: integrins at the basis of iPSC cardiomyocyte differentiation. Stem Cells Int. 2019;2019:1–20. doi: 10.1155/2019/8203950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hansson J, et al. Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep. 2012;2:1579–1592. doi: 10.1016/j.celrep.2012.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ohta S, Nishida E, Yamanaka S, Yamamoto T. Global splicing pattern reversion during somatic cell reprogramming. Cell Rep. 2013;5:357–366. doi: 10.1016/j.celrep.2013.09.016. [DOI] [PubMed] [Google Scholar]
  • 42.Nakagawa M, et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci. Rep. 2014;4:3594. doi: 10.1038/srep03594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. doi: 10.1093/nar/28.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28:1947–1951. doi: 10.1002/pro.3715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucl. Acids Res. 2021;49:D545–D551. doi: 10.1093/nar/gkaa970. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES